OVERVIEW
========

Research over the past decade has extended the prevailing view of the mitochondrion to include functions well beyond the critical bioenergetics role of supplying ATP to include cell signaling events, inter-organellar communication, aging, cell proliferation, a target in disease, and apoptosis. Mitochondria thus play a central role in the regulation of apoptosis and serve as the venue for cellular decisions leading to cell life or death. One of the mitochondrial proteins controlling cell life and death is the voltage-dependent anion channel (VDAC), also known as mitochondrial porin. VDAC, located in the mitochondrial outer membrane, functions as gatekeeper for the entry and exit of mitochondrial metabolites, thereby controlling cross-talk between mitochondria and the rest of the cell. VDAC is also a key player in mitochondria-mediated apoptosis. Thus, in addition to regulating the metabolic and energetic functions of mitochondria, VDAC appears to act as a convergence point for a variety of cell survival and cell death signals, mediated by its association with various ligands and proteins. The focus of this review will be on the central role of VDAC in cell life and death, addressing VDAC function in the regulation of mitochondria-mediated apoptosis, with an emphasis on structure--function relationships. Understanding VDAC structure--function relationships is critical for deciphering how this channel can perform such a variety of functions, all important for cell life and death. Finally, this review will also provide insight into VDAC function in Ca^2+^ homeostasis, protection against oxidative stress, regulation of apoptosis, and involvement in several diseases, as well as its role in the action of different drugs.

VDAC: ISOFORMS, LOCATION, AND TRANSPORT ACTIVITY
================================================

VDAC ISOFORMS
-------------

In mammals, three homologous genes encode three VDAC isoforms, namely VDAC1, VDAC2, and VDAC3 ([@B346]). The three proteins have similar molecular weights (30--35 kDa), each shares approximately 70% identity, and all three can be found in most tissues, albeit in different amounts, with the most abundant sub-type being VDAC1 and the least common form being VDAC3 ([@B76]; [@B422]; [@B110]; [@B346]; [@B260]). VDAC1 and VDAC2 but not VDAC3 can form a channel upon reconstitution into an artificial lipid bilayer, with VDAC1 showing voltage-gated high conductance channel properties (see Channel Activity of VDAC1). VDAC2 also presents normal gating activity, while VDAC3 does not insert readily into membranes and generally does not gate well, even at high membrane potentials (up to 80 mV; [@B324]; [@B419]).

The specific role of each VDAC isoform remains unclear, although evidence indicates that they serve different physiologic functions ([@B324]; [@B419]; [@B416]). For example, the absence of VDAC1 caused multiple defects in respiratory complex activities in both skeletal and cardiac muscle, while in VDAC3-deficient mice, these defects are restricted to the heart ([@B12]), suggesting that *in vivo*, these two isoforms fulfill distinct physiologic roles. In mice, *vdac1* and *vdac2* deletion reduces respiratory capacity ([@B416]), the absence of VDAC3 causes male sterility, and a lack of both VDAC1 and VDAC3 causes inhibited growth ([@B323]). Furthermore, it was demonstrated that VDAC1- and VDAC3-lacking mice show deficits in learning behavior and synaptic plasticity ([@B409]). VDAC3-lacking mice were male-infertile because their mitochondria and the axoneme of their sperm are structurally altered ([@B323]). Finally, *vdac1-* and *vdac3-*deficient mice are viable, whereas embryos with a homozygous deletion of *vdac2* die during development ([@B78]).

VDAC1 interacts with different proteins and factors, such as hexokinase (HK; [@B3]) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH; [@B377]), while biochemical data indicate that VDAC1 but not VDAC2 binds HK ([@B48]). This, however, has been questioned ([@B21]). Lately, it was demonstrated that HK-I and VDAC3 exhibit a higher degree of mitochondrial co-localization than does HK-I with either VDAC1 or VDAC2 ([@B270]).

Large proteomic surveys and other studies have shown that all three VDAC isoforms are subject to both phosphorylation and acetylation at multiple sites ([@B121]; [@B406]; [@B83]; [@B138]; [@B259]; [@B197]). Analysis of the amino acid sequence of VDAC1 showed that the first methionine is deleted, while the second amino acid, an alanine, is acetylated ([@B194]; [@B138]). Among the other post-translation modifications VDAC1 undergoes are phosphorylation of serine, threonine, and tyrosine residues ([@B121]; [@B197]) and acetylation of lysines ([@B198]; [@B330]; [@B442]; [@B423]). Recently glycogen synthase kinase 3 (GSK3)-mediated VDAC phosphorylation was reported, allowing for control of outer mitochondrial membrane (OMM) permeabilization in hepatosteatosis ([@B248]). Currently, the effects of these modifications on VDAC activity are not clear.

VDAC LOCATION AND METABOLITE TRANSPORT
--------------------------------------

VDAC is localized to the OMM of all eukaryotes ([@B38]), where it assumes a crucial position in the cell, serving as the main interface between mitochondrial and cellular metabolisms. VDAC is permeable to uncharged molecules up to ∼5,000 Da in the open configuration, mediating the flux of ions, nucleotides and other metabolites across the OMM ([@B346]; **Figure [1](#F1){ref-type="fig"}**). In keeping with its two-way trafficking role, VDAC1 enables substrates, including pyruvate, malate, succinate, and NADH, to enter the mitochondria and mediates the exit of newly formed molecules, such as hemes ([@B346]). Hence, down-regulation of VDAC1 expression results in reduced metabolite exchange between mitochondria and the cytosol, making VDAC1 essential for energy production and cell growth ([@B2]). Similarly, alterations in mitochondrial function are linked to VDAC closure, which limits the normal flow of metabolites in and out of mitochondria ([@B393]; [@B181]). VDAC1, at the OMM, is also involved in the entry and exit of Ca^2+^ (see VDAC1 Transport of Ca^2+^ and Function in ER-mitochondria Cross-talk). VDAC, furthermore, functions in cholesterol transport across the OMM ([@B311]). Indeed, VDAC has been proposed to be a necessary component of a protein complex involved in mitochondrial membrane cholesterol distribution and transport and to play an important role in altered cholesterol synthesis and transport in Morris hepatoma cells ([@B67]).

![**Schematic representation of VDAC1 as a multi-functional channel and convergence point for a variety of cell survival and cell death signals.** The various functions of VDAC1 include control of the metabolic cross-talk between the mitochondria and the rest of the cell, cellular energy homeostasis by transporting ATP/ADP and NADH between the inter-membrane space and the cytosol and by binding HK, signaling by transporting Ca^2+^, ROS release to the cytosol and apoptosis, both by binding to the apoptosis regulatory proteins, Bcl-2 family and HK. Also presented are the Ca^2+^ influx and efflux transport systems in the outer and inner mitochondrial membranes and Ca^2+^-mediated regulation of the tricarboxylic acid (TCA) cycle. The activation of pyruvate dehydrogenase (PDH), isocitrate dehydrogenase (ICDH) and α-ketoglutarate dehydrogenase (αKGDH) by intra-mitochondrial Ca^2+^, leading to enhanced activity of the TCA cycle, is shown. The electron transport chain (ETC) and the ATP synthase (F~o~F~1~) are also presented. VDAC in the OMM is presented as a Ca^2+^ channel. In the IMM, the uptake of Ca^2+^ into the matrix is mediated by a Ca^2+^-selective transporter, the mitochondrial Ca^2+^ uniporter (MCU), regulated by a calcium-sensing accessory subunit (MICU1). Ca^2+^ efflux is mediated by NCLX, a Na^+^/Ca^2+^ exchanger. High levels of matrix Ca^2+^ accumulation trigger the opening of the PTP, a fast Ca^2+^ release channel. Molecular fluxes are indicated by arrows.](fonc-02-00164-g001){#F1}

Given its location at the boundary between the mitochondria and the cytosol, VDAC1 is able to interact with proteins that mediate and regulate the integration of mitochondrial functions with other cellular activities. VDAC1 interacts with HK and creatine kinase to convert newly generated ATP into high-energy storage forms, like glucose-6-phosphate (G-6-P) and creatine phosphate, in brain and muscle, respectively. The over-expression of VDAC1 in some cancer cells may be related to its multi-functional activities, as required by high energy-demanding cells ([@B348]; see VDAC Expression Levels in Cancers and Enhancement by Pro-apoptotic Drugs).

Thus, VDAC is a dynamic regulator of global mitochondrial function both in health and disease ([@B224]).

EXTRA-MITOCHONDRIAL LOCALIZATION OF VDAC
----------------------------------------

VDAC1 was once thought to be localized solely to the OMM ([@B431]). Indeed, although VDAC is present in abundance in the OMM, various studies have revealed that VDAC is also localized to cell compartments other than mitochondria ([@B31]; [@B350]; [@B111]). VDAC, first isolated from human plasma membrane lymphocytes ([@B381]), was subsequently detected in other cells of various tissues ([@B31]; [@B111]). A splice variant of the mitochondrial VDAC1 gene encoding a leader peptide of 13 amino acids at the NH~2~ terminus was detected and termed plasmalemmal VDAC1 (pl-VDAC1; [@B63]). The protein from this splice variant exhibited extra-mitochondrial trafficking to the endoplasmic reticulum (ER), the Golgi apparatus, and the plasma membrane ([@B156]; [@B111]). Caveolae and caveolae-like domains were shown to contain VDAC ([@B32]). The extra-mitochondrial localization of VDAC in bovine outer dense fibers, a cytoskeletal component of the sperm flagellum, has been reported ([@B179]; [@B386]; [@B72]). VDAC2 was shown to be present in the membrane components of human spermatozoa ([@B233]). The presence of VDAC in the sarcoplasmic reticulum (SR) of amphibian and mammalian skeletal muscle and in the ER of rat cerebellum has also been demonstrated ([@B349], [@B353]; [@B350]).

The exact functions of the extra-mitochondrial VDAC are as yet unknown. pl-VDAC1 was suggested to facilitate regulatory volume decrease in epithelial cells and to play a role in cellular ATP release and volume control ([@B275]). The possible functions of VDAC in the SR/ER include providing a pathway for transport of Ca^2+^, nucleotides and other metabolites across the membrane, and involvement in apoptosis. The participation of VDAC in supra-molecular complexes and intracellular communication, including calcium signal delivery between the ER and mitochondria, has also been postulated ([@B350]; see VDAC1 Transport of Ca^2+^ and Function in ER-mitochondria Cross-talk).

CHANNEL ACTIVITY OF VDAC1
=========================

VDAC CONDUCTANCE, ION SELECTIVITY, AND VOLTAGE-DEPENDENT CHANNEL GATING
-----------------------------------------------------------------------

The channel properties of VDAC1 have been examined following reconstitution of the purified protein into a planar lipid bilayer (PLB). VDAC1 has been purified using various procedures and detergents ([@B346]). Bilayer-reconstituted VDAC1 assumes multiple voltage-dependent conformational states, displaying different selectivities and permeabilities. VDAC1 shows symmetrical bell-shaped voltage-dependent conductance with the highest conductance (4 nS at 1 M KCl) at low potentials of -20 to +20 mV ([@B88]; [@B38]; **Figure [2](#F2){ref-type="fig"}**). At low potentials, when in the fully open state, VDAC1 selectively conducts small ions (e.g., Cl^--^, K^+^, Na^+^), yet shows a preference for anions, such as phosphate, chloride, adenine nucleotides, glutamate, and other anionic metabolites, and large cations, such as acetylcholine, dopamine, and Tris ([@B346]). At higher positive or negative potentials (\>30--60 mV), the channel conductance is reduced and the selectivity shifts to small cations. In this scenario, the channel becomes virtually impermeable to ATP and ADP ([@B88]; [@B38]; [@B346]).

![**Proposed three-dimensional structure of VDAC1. (A)** Side-view of the X-ray crystal structure of mouse VDAC1 ([@B392]) in a ribbon representation. The β-barrel is formed by 19 β-strands and the N-terminal helix is folded into the pore interior. β-strands 1 and 19 are parallel and colored blue. The C- and N-termini are annotated as C and N, respectively. Loops and unstructured regions are colored green. **(B)** Top-view of VDAC1 with the N-terminal inside the pore. **(C)** VDAC1 in a proposed conformation with the N-terminal outside the channel where it can interact with other proteins (PDB code: 3EMN).](fonc-02-00164-g002){#F2}

As a voltage-gated channel, VDAC1 must possess a voltage sensor to respond to changes in transmembrane voltage. It is believed that VDAC1 channels rely on two separate gating processes, one that occurs at positive transmembrane potentials and the other at negative potentials ([@B361]). The N-terminal α-helical segment of the channel has been proposed to act as the voltage sensor, gating the pore via conformational changes and/or movements (see The N-terminal Region of VDAC1: Location, Translocation and Channel Gating). Clearly, the molecular nature of VDAC1 gating mechanism has not yet been resolved.

VDAC CHANNEL MODULATORS AND INHIBITORS
--------------------------------------

Despite the critical involvement of VDAC1 in various mitochondrial functions, little is known of how VDAC is regulated. Accumulated evidence suggests that VDAC1 function is modulated by various physiological ligands, such as glutamate, adenine nucleotides, NADH, and non-physiological compounds, such as Koenig's polyanion, ruthenium red (RuR), dicyclohexylcarbodiimide (DCCD), and 4,4′-diisothiocyanatostilbene-2,2′-disulfonic acid (DIDS; [@B351]).

NADH was found to regulate the gating of mammalian, fungal, and plant VDAC ([@B220]). For mammalian VDAC1, molecular and biochemical evidence indicates that the protein possesses one or more nucleotide-binding site(s) ([@B317]; [@B427], [@B426]). Glutamate specifically, but not aspartate or GABA, eliminates the bell shape of VDAC voltage-dependence channel conductance ([@B148]). Accumulating evidence also suggests that VDAC possesses regulatory binding sites for Ca^2+^ (reviewed in [@B347]; [@B351]).

Various compounds targeting apoptotic cell death or cell proliferation were found to mediate their activity via interaction with VDAC1, modulating VDAC1 activity (see VDAC as a Pharmacological Target for Compounds Affecting Cell Proliferation or Apoptosis). In addition, VDAC1, acting as a docking site for various proteins, is regulated via protein--protein interactions. Specifically, HK, Bcl2, Bcl-xL, actin, and tubulin were found to interact with VDAC1 and alter its channel conductance (see VDAC1 Association with Proteins and Cancer).

Finally, high cholesterol, known to reduce the activity of membrane-associated proteins, was found to inhibit channel conductance and the metabolic function of VDAC ([@B67]). It has also been reported that plant VDAC undergoes a reversible regulation of selectivity and voltage-dependence in the presence of sterols ([@B265]).

VDAC STRUCTURE--FUNCTION RELATIONSHIPS
======================================

Since their discovery in the mid-1970s, great efforts have been devoted to understanding structure--function relationships of VDACs using numerous techniques, including circular dichroism (CD), atomic force microscopy (AFM), electron microscopy, NMR, crystallography, and others.

THE THREE-DIMENSIONAL STRUCTURE OF hVDAC1
-----------------------------------------

VDAC1 is a polypeptide of 283 amino acids with Met1 missing in the mature protein ([@B381]; [@B48]). Various studies have led to the development of models postulating the transmembrane organization of VDAC1, comprising a single α-helix at the N-terminus and 13, 16, or 19 transbilayer β-strands that form a β-barrel ([@B113]; [@B361]; [@B71]; [@B89]).

Recently, the 3D structure of recombinant VDAC1 was solved using X-ray crystallography, NMR and a combination of the two. Such studies presented VDAC1 as composed of 19 β-strands arranged as a barrel, with strands β1 and β19 being in parallel conformation (**Figure [3](#F3){ref-type="fig"}**; [@B35]; [@B178]; [@B392]). The N-terminal domain of VDAC1, consisting of 25 amino acids, was shown to be very dynamic and possesses different degrees of α-helical content in each of the three proposed structures ([@B35]; [@B178]; [@B392]). All three methods employed refolded recombinant VDAC1 expressed in *E. coli* and purified from inclusion bodies. As such, it has been argued that the refolding conditions employed led to the appearance of non-native structures, as biochemical and biophysical approaches argue for the existence of additional extra-membranal VDAC regions ([@B90]).

![**Channel properties of bilayer-reconstituted purified VDAC1.** Bilayer-reconstituted VDAC single and multi-channel activity was assayed as described previously ([@B148]). Purified VDAC (1--5 ng) was reconstituted into a PLB. In **(A)**, a typical activity recording of VDAC incorporated into a PLB is presented as current traces obtained in response to voltage steps from 0 mV to either -10 or -60 mV. In symmetric solution (1 M NaC), when the voltage was changed from -0 to 10 mV, the channel opens and remains stable in this conformation for up to 2 h. However, when the voltage was changed from 0 to -60 mV, the current first increased, due to a greater driving force. However, within less than 1 s, channel conductance decreased and VDAC assumed multiple conductance states. The dashed line indicates the zero current level, while the sub-states of the channel are indicated by arrowheads. In **(B)**, Multi-channel recordings of the average steady-state conductance of VDAC are presented as a function of voltage. The conductance (*G*~o~) at a given voltage was normalized to the conductance at -10 mV (*G*~max~). Each point is the average of three experiments. This voltage-dependent behavior is well known for VDAC.](fonc-02-00164-g003){#F3}

The pore diameter of the channel has been estimated to be between 3 and 3.8 nm, based on biochemical and structural methods ([@B87]; [@B155]; [@B35]) and about 1.5 nm when the N-terminal α-helix is located inside the channel, according to the recent 3D studies ([@B35]). Finally, there is evidence that cholesterol is bound to mammalian mitochondrial VDAC and sterols seem to be important for the folding of VDAC ([@B109]; [@B178]).

THE N-TERMINAL REGION OF VDAC1: LOCATION, TRANSLOCATION, AND CHANNEL GATING
---------------------------------------------------------------------------

The location of the N-terminal region of VDAC1 with respect to the pore, its role in voltage-gating and its interaction with associated proteins have been the focus of intensive study, as described below.

### Location and translocation of the N-terminal region

The VDAC N-terminal region was proposed to lie on the membrane surface ([@B307]), to be exposed to the cytoplasm ([@B112]) or to cross the membrane ([@B89]). The 3D structures of recombinant VDAC1, however, revealed that the N-terminal domain is located inside the channel pore, causing a partial obstruction of the wide pore, possibly providing structural reinforcement to the channel walls ([@B35]; [@B178]; [@B392]; [@B328]; **Figure [3](#F3){ref-type="fig"}**). Deletion of the N-terminal helical domain did not affect the correct mitochondrial targeting of the protein ([@B115]).

Various studies suggesting that the N-terminal region of VDAC1 constitutes a mobile component of the protein (see VDAC1 N-terminal Domain Function in Voltage-gating and Cell Death). In 2D crystals of *Neurospora crassa* VDAC1, oblique arrays of the N-terminal domain appear to extend laterally from the barrel, into the aqueous phase ([@B163]). The N-terminus of the protein was shown to be accessible to anti-VDAC1 antibodies raised against this part of the protein ([@B163]; [@B353]; [@B2]). The same domain is exposed to kinases, as threonine-13 undergoes phosphorylation ([@B121]). Additionally, the N-terminal domain of VDAC1 interacts with cytosolic proteins and acts as a recruiting site for HK1, Bcl2, and Bcl-xL and thus is a key structural feature mediating VDAC interaction with anti-apoptotic proteins to enable their function ([@B335]; [@B1]; [@B19]; [@B18]), suggesting that this VDAC region is exposed outside the pore. Finally, a recent *in silico* study supports the role of the N-terminal in controlling shape and permeability of the channel. In the absence of N-terminal, increased overall β-barrel motion, resulting in elliptic, semi-collapsed barrel shapes, is seen ([@B434]).

Taken together, these findings suggest that the N-terminal region of VDAC1 is loosely attached to the barrel wall and can undergo translocation to become exposed at the membrane surface. This movement allows VDAC1 to interact with the anti-apoptotic proteins, HK, Bcl-xL, and Bcl2, and may participate in VDAC1 oligomerization. The signal and nature of conformational changes inducing VDAC1 N-terminal region translocation, both under physiological and apoptotic conditions, await further study.

### VDAC1 glycine-rich sequence

It was reported that in VDAC1, a glycine-rich sequence (GXXXG), highly conserved in mammals, connects the N-terminal domain to the β-barrel, thus providing the flexibility needed for N-terminal translocation in and out of the pore ([@B143]). When this flexible region is mutated by replacing glycines with prolines, the N-terminal region favors a location out of the pore, thereby affecting channel gating. Moreover, in such mutants, the ability to form VDAC1 dimers was highly increased. The GXXXG motif has been linked with dimerization in proteins such as glycophorin A ([@B142]), human carbonic anhydrase ([@B412]), yeast ATP synthase ([@B320]), carnitine palmitoyltransferase ([@B188], and others). In VDAC1, this motif is not required for VDAC1 dimerization but may be involved in interaction with VDAC1-associated proteins ([@B143]). Interestingly, such a motif in Bcl-xL, interacting with VDAC1 ([@B17]), has been recently suggested to mediate VDAC interaction with other proteins ([@B277]).

### VDAC1 N-terminal domain function in voltage-gating and cell death

It was reported that during voltage-gating or interaction with molecules, such as cytochrome *c* (Cyto *c*), some motion of VDAC occurred ([@B363]). N-terminal-truncated mV DAC1 was shown to exhibit high conductance at all tested voltages and was proposed to be a main effector in those apoptotic events dependent on VDAC1 ([@B114]; [@B1]). Using recombinant mutated VDAC1 with the N-terminal cross-linked to channel wall, it was shown that voltage-gating was modified but not completely lost ([@B378]). On the other hand, mobility of the N-terminal region and the contribution of this domain to channel gating and interaction with anti-apoptotic proteins were recently demonstrated using site-directed mutagenesis and cysteine substitution, together with a thiol-specific cross-linker ([@B143]). Swapping the N-terminal domain of VDAC1 and with that of VDAC3 restores full activity of the channel ([@B306]).

Different models for the voltage-dependent gating of VDAC1 via the N-terminal region have been proposed: (i) Blockage of the pore by movement of the N-terminal domain within the lumen from the barrel wall toward the center of the channel ([@B178]; [@B392]); (ii) transition of the N-terminal region from an α-helical structure that aligns with the barrel wall to a less-structured, unfolded helix element that interacts with the opposing barrel wall ([@B35]; [@B368]), and (iii) movement of the N-terminal region into and out of the channel lumen ([@B114]; [@B1]; [@B143]; [@B378]). Calculations using both Poisson--Boltzmann and Poisson--Nernst--Planck electrostatic equations agree with the N-terminal region being involved in gating but not via lateral or horizontal movement of the helix ([@B84]). Thus, the accumulated results and the derived models point to the N-terminal domain as being involved in the channel gating, although the precise mechanism has yet to be described.

### VDAC1 C-terminal domain

In contrast to the extensive studies directed at defining N-terminal domain structure--function, very little research effort has addressed the VDAC1 C-terminal domain. Recently, a frame-shift resulting in appearance of an early stop codon in the VDAC1 gene, leading to the absence of approximately 60% of the C-terminal portion of VDAC1, was noted in gastric and colonic cancers with microsatellite instability ([@B429]). Patients with this somatic mutation are heterozygous ([@B429]).

A link between the VDAC1 C-terminal region and cancer also comes from studies connecting hypoxia and C-terminal cleavage ([@B54]). Hypoxic conditions were found to trigger cleavage of the VDAC1 C-terminal to yield a 26-kDa protein ([@B54]). This C-terminal-cleaved VDAC1 was regulated by HIF-1α and was correlated with hypoxic cell survival and chemotherapy resistance ([@B54]). Based on the incidence of δC-VDAC1 in lung cancer (about 50% on average and higher in late stage tumors), this form of the protein was proposed to serve as a biomarker to stratify tumor progression in lung cancer patients ([@B54]). Finally, it was reported that an unidentified mitochondrial calpain cleaves the apoptotic induction factor (AIF) and VDAC1 in a Ca^2+^-dependent manner, and that such cleavage triggers tVDAC--Bax pores that are associated with the release of tAIF ([@B280]).

VDAC1 OLIGOMERIZATION AND FUNCTION
----------------------------------

Purified and membrane-embedded mammalian VDAC1 were shown to assemble into dimers, trimers, tetramers, and higher oligomers, as revealed by chemical cross-linking and fluorescence resonance energy transfer (FRET) analysis ([@B436]). A low-resolution (15 Å) surface structure of VDAC1, obtained by metal shadowing and cryo-electron microscopy of human VDAC1 crystals grown in the presence of phospholipids, showed a dimeric organization of VDAC1 ([@B123]). High-resolution AFM of purified native OMM from potato tubers ([@B182]) or yeast ([@B155]) showed the distribution of VDAC in an equilibrium ranging from single membrane-embedded pores to hexamers and higher-order oligomers ([@B182]), including arrays of up to 20 molecules ([@B155]). In addition, the use of symmetry operators on the NMR-based structure of recombinant hVDAC1 implied that it forms a dimer of monomers arranged in parallel ([@B35]), while analysis of the crystal packing of mVDAC1 revealed strong anti-parallel dimers that further assemble into hexamers ([@B391]).

Interestingly, VDAC1 oligomerization is highly increased upon apoptosis induction ([@B196]). Structural and computational-based approaches, in combination with site-directed mutagenesis, cysteine replacement, and chemical cross-linking, identified the contact sites between VDAC1 molecules in dimers and higher oligomers ([@B144]). Two forms of dimeric VDAC1, one with a contact site involving β-strands 1, 2, and 19 and the second involving β-strands 16 and 17, were identified. Moreover, the results suggest that VDAC1 exists as a dimer that undergoes conformational changes upon apoptosis induction to assemble into higher oligomeric states with contact sites also involving β-strand 8 ([@B144]).

The function of VDAC1 oligomers is not known. It was proposed that an organization of VDAC1 beyond the monomeric or dimeric forms may contribute to stabilizing the protein ([@B391]). On the other hand, it was proposed that the oligomeric assembly of VDAC1 offers a platform for other proteins to oligomerize, such as HK ([@B436]). HK-I assumes a tetrameric structure that is greatly enhanced when the enzyme is bound to mitochondria ([@B417]) or when it interacts with the mitochondria to inhibit permeability transition pore (PTP) opening ([@B22]). Creatine kinase, when bound to VDAC1 at the inter-membrane space, forms high order oligomers ([@B56]; [@B362]), interacting with VDAC1 exclusively in the octameric state, with the dimeric state only showing weak affinity for VDAC1 ([@B327]).

Recently, the function of VDAC1 oligomerization in apoptosis, namely mediating the pathway for the release of Cyto *c*, was proposed ([@B436]; [@B351], [@B344]; [@B1]; [@B196]). VDAC1 oligomerization was strongly correlate with apoptosis induction ([@B344], [@B352]; [@B1]; [@B196]), while apoptosis induction by various inducers was accompanied by an up to 20-fold increase in VDAC1 oligomerization, indicating a shift in VDAC1 organization toward the oligomeric form under such conditions ([@B344]; [@B196]; see VDAC1 Oligomerization and Release of Cytochrome *c*).

VDAC1 AND MITOCHONDRIA-MEDIATED APOPTOSIS
=========================================

In apoptosis, a multi-step process that can be initiated by a variety of stimuli, a cascade of cysteine proteases, caspases, are activated, subsequently leading to organized cell demise. Defects in the regulation of apoptosis are often associated with various diseases, with the ability of cells to evade apoptosis being a hallmark of cancer ([@B171]). Alterations of apoptosis are involved in tumorigenesis, as well as in cellular responses to anti-tumor treatments ([@B177]; [@B191]).

THE EXTRINSIC AND INTRINSIC APOPTOTIC PATHWAYS
----------------------------------------------

Apoptosis can be activated via the extrinsic or intrinsic pathways. In the extrinsic pathway, apoptosis is induced by extrinsic apoptotic signals initiated by ligand engagement of cell surface receptors, such as Fas and TNF receptors. The intrinsic pathway is initiated in mitochondria in response to different stimuli ([@B158]; [@B191]; [@B85]). Receptor binding by an extrinsic signal typically leads to the recruitment of adapter proteins that promote caspase oligomerization and auto-processing. The extrinsic apoptotic pathway can induce activation of the intrinsic pathway via caspase 8-dependent cleavage of Bid and translocation of the truncated form (tBid) to the mitochondria ([@B209]; [@B428]). Thus, apoptotic signals initiated by death receptors can be linked to mitochondria-mediated apoptosis.

The intrinsic apoptotic pathway involves mitochondria. Mitochondria contain an arsenal of apoptogenic factors, normally residing in the inter-membranal space (IMS), such as Cyto *c*, AIF, Smac/DIABLO, and endonuclease G. During transduction of an apoptotic signal into the cell, an alteration in mitochondrial permeability occurs, causing the release of these apoptogenic factors from the IMS ([@B158]; [@B85]; [@B346]). These proteins participate in complex processes resulting in the activation of proteases and nucleases, leading to protein and DNA degradation, and ultimately, cell death. Most notable among the released protein is Cyto *c* that initiates apoptosis by binding to a central apoptotic regulator, Apaf-1, promoting oligomerization of Apaf-1 and activation of caspase 9, which subsequently activates effector caspases, such as caspases 3, 6, and 7, encouraging execution of cell death. How Cyto *c* and other apoptogenic factors are released from mitochondria is not clear, and will be discussed below.

Mitochondria-mediated apoptosis can be induced in response to different stimuli ([@B93]), including high levels of cytoplasmic Ca^2+^, reactive oxygen species (ROS), activation of pro-apoptotic Bcl-2 family proteins ([@B219]; [@B195]; [@B212]) or UV damage ([@B107]). Chemotherapeutic agents act via different mechanisms to induce mitochondria-dependent apoptosis ([@B93]). These include betulinic acid ([@B134]), PK11195 ([@B180]), diamide ([@B439]), lonidamine (LND; [@B304]), arsenite ([@B218]), 6\[3-adamantyl-4-hydroxyphenyl\]-2-naphthalene carboxylic acid (CD437; [@B247]), 2-chloro-2′-deoxyadenosine, 2-chloro-2′-ara-fluorodeoxy-adenosine ([@B141]), MT-21 ([@B408]), verteporfin ([@B37]), resveratrol ([@B383]), and paclitaxel ([@B11]).

As mitochondria represent an appropriate target for therapeutic agents designed to modulate apoptosis, continued research into the mechanisms of mitochondria-mediated apoptotic cell death, coupled with further characterization of the released molecules, will offer new and promising targets for chemotherapeutic intervention in a host of pathologies.

VDAC1 AND APOPTOSIS
-------------------

The involvement of VDAC1 in mitochondria-mediated apoptosis has been proposed based on several lines of experimental evidence: (a) Anti-VDAC1 antibodies specifically and effectively prevent As~2~O~3~-induced Cyto *c* release from isolated mitochondria ([@B443]) and when microinjected into cells, prevented Bax-induced Cyto *c* release and subsequent apoptosis, as well as etoposide-, paclitaxel-, and staurosporine (STS)-induced apoptosis ([@B339]). Anti-VDAC1 antibodies also inhibited the interaction of Bax with VDAC and the triggering of cell death ([@B241]; [@B339]; [@B443]). Microinjection of anti-VDAC antibodies into primary rat hepatocytes effectively prevents apoptosis and Bax--VDAC interactions, as induced by ethanol ([@B4]); (b) VDAC1 is the proposed target of pro- and anti-apoptotic members of the Bcl2 family and of HK-I and HK-II ([@B339]; [@B335]; [@B22]; [@B435]; [@B18]; see VDAC1 Transport of Ca^2+^ and Function in ER-mitochondria Cross-talk); (c) inhibition of Cyto *c* release and cell death mediated by HK occurred in cells expressing native but not mutated VDAC1 ([@B435]; [@B3]; [@B19]); (d) RuR, interacting with Ca^2+^-binding proteins, interacts with native but not mutated VDAC1 to prevent Cyto *c* release and cell death ([@B435]; [@B186]); (e) siRNA-mediated down-expression of VDAC1 prevented cell death and activation of Bax induced by cisplatin and strongly reduced cisplatin-induced release of Cyto *c* and AIF, as well as the maturation of caspases-3 ([@B373]). Similarly, reducing VDAC1 expression by siRNA attenuated endostatin-induced apoptosis ([@B433]); (f) over-expression of human, murine, yeast, and rice VDAC induce apoptotic cell death ([@B150]; [@B435]; [@B3]); (g) knockdown of VDAC1 in non-small cell lung cancer (NSCLC) cells inhibited TRAIL-induced activation of caspase-8 and subsequent apoptosis ([@B77]); and (h) release of Cyto *c* was obtained using purified VDAC1 reconstituted into liposomes in which Cyto *c* had been encapsulated ([@B241]; [@B436]). Finally, (i) growth factor removal from the medium resulted in reduced nucleotide exchange between mitochondria and cytosol, leading to Cyto *c* release and apoptosis ([@B393]).

In general, there are two views as to the relationship between the conducting state of the VDAC1 channel and cell death. While one view suggests that closure, rather than opening of VDAC leads to OMM permeabilization and apoptosis ([@B393]), the second model suggest a distinct VDAC1-based conducting pathways, namely a pore formed in the center of a VDAC1 oligomer ([@B340]; [@B436]; [@B351]; see VDAC1 Oligomerization and Function).

PROPOSED MECHANISMS OF CYTOCHROME *c* RELEASE FROM THE MITOCHONDRIA
-------------------------------------------------------------------

Several proposals regarding the mechanism of Cyto *c* crossing the OMM have been proposed (**Figure [4](#F4){ref-type="fig"}**). However, none of the current models of mitochondrial membrane permeabilization can account for all of the experimental data.

![**Schematic representation of proposed models for the release of apoptogenic proteins from the mitochondrial inter-membrane space mediating the mitochondrial death decision.** Different models explaining how OMM permeability changes during apoptosis induction, allowing the release of apoptogenic factors, such as Cyto *c*. **(A)** A permeability transition pore (PTP) provides the apoptogenic proteins release pathway. It is proposed that a large conductance pore-forming complex, the PTP, composed of VDAC at the OMM, ANT at the IMM and CypD in the matrix, allows apoptogenic protein release. **(B)** VDAC closure and OMM rupture serves as the cytochrome c release pathway. Prolonged VDAC closure leads to mitochondrial matrix swelling, OMM rupture, and hence, the appearance of a non-specific release pathway for apoptogenic proteins. **(C)** Bax activation followed by its oligomerization resulting in OMM permeabilization. Upon apoptosis induction, Bax became associated with mitochondria as a large oligomer/complex, forming a Cyto *c*-conducting channel in the OMM. **(D)** A pore formed by oligomerized forms of Bax and Bak after their activation by tBID. BH3-only proteins (e.g., Bid) induce oligomerization of Bax/Bak on the OMM, resulting in Bax activation and OMM permeabilization. **(E)** MAC as the release pathway. The mitochondrial apoptosis-induced channel, MAC, is a high-conductance channel that forms during early apoptosis and is a putative cytochrome *c* release channel. MAC formation occurs without loss of outer membrane integrity and depolarization. Members of the Bcl-2 family of proteins regulate apoptosis by controlling the formation of MAC. **(F)** A Bax- and VDAC-based hetero-oligomer mediates cytochrome c release. The interaction of pro-apoptotic proteins (Bax/Bak) with VDAC forms a cytochrome *c* release pathway. **(G)** A lipid channel formed by the lipid, ceramide. Ceramides were shown to induce apoptosis via direct action on mitochondria. A self-assembled ceramide channel is proposed to act as the apoptotic protein release pathway. **(H)** Oligomeric VDAC1 as a channel for the release of apoptotic proteins. A protein-conducting channel is formed within a VDAC1 homo-oligomer. VDAC1 oligomerization thus functions in mitochondria-mediated apoptosis (see VDAC1 Oligomerization and Release of Cytochrome *c*). The dynamic equilibrium between VDAC monomeric and oligomeric states can be regulated by various factors, such as Ca^2+^, oxidative stress and cytochrome *c*.](fonc-02-00164-g004){#F4}

In healthy cells, Cyto *c* is located in the mitochondrial IMS, where it serves as an electron shuttle between complexes III and IV of the respiratory chain, with most Cyto *c* being bound to cardiolipin (CL). Signals inducing mitochondria-mediated apoptosis result in the release of IMS proteins, including Cyto *c* (see The Extrinsic and Intrinsic Apoptotic Pathways). The mechanisms by which Cyto *c* and other pro-apoptotic effector molecules are released have challenged many researchers and several competing models have been proposed to explain the workings of this event (**Figure [4](#F4){ref-type="fig"}**; [@B343]). While some models suggest that the proteins crossing the OMM exclusively involve an increase in OMM permeability due to the formation of a channel large enough to allow for the release of proteins, such as Cyto *c*, others consider efflux of the proteins to be due to disruption of OMM integrity. The following briefly describes the various proposed models:

### The permeability transition pore and the release of pro-apoptotic proteins

One model (Model A, **Figure [4](#F4){ref-type="fig"}**) for mitochondrial membrane permeability (MMP) suggests the formation of a PTP, a large high-conductance multi-protein complex comprising several components and spanning both mitochondrial membranes ([@B39]; [@B225]; [@B166]; [@B347]; [@B390]). PTP opening is followed by Ca^2+^ accumulation in the matrix, leading to a sudden increase in permeability to solutes (up to 1,500 Da; [@B39]; [@B225]; [@B166]; [@B347]; [@B390]). This Ca^2+^-dependent increase in MMP leads to loss of membrane potential, mitochondrial swelling, and rupture of the OMM. According to this model, other factors, such as changes in the energetic balance of the mitochondria, anoxia, and ROS can also induce MMP due to PTP opening (reviewed in [@B390]).

The proposed PTP complex components include VDAC1 at the OMM, ANT in the inner mitochondrial membrane (IMM), and cyclophilin D (CypD) in the matrix ([@B39]; [@B158]; [@B347]; [@B390]). Recent studies on the PTP, however, have raised doubts about the proposed members of the complex and the importance of PTP in triggering apoptosis ([@B211]; [@B205]; [@B36]). Mitochondria isolated from animal models by knockout of genes encoding one or more ANT or VDAC isoforms exhibit Ca^2+^- and oxidative stress-induced PTP opening, suggesting that the proposed components of the standard model of the PTP complex needs to be reconsidered and further characterized ([@B205]; [@B210]; [@B26]; [@B41]). On the other hand, CypD was found to be essential for MMP mediated by Ca^2+^ overload and that the CypD-dependent MMP regulates some forms of necrotic cell death but not apoptotic death ([@B36]).

Although the mechanism(s) responsible for PTP opening and its physiological function have not yet been resolved, a variety of agents were found to promote or inhibit PTP opening, including Ca^2+^, inorganic phosphate, various oxidizing agents, glutamate, nucleotides, CypD ligands, gelsolin, HK, and proteins of the Bcl-2 family. Some of these compounds have also been shown to interact with VDAC1 directly and modify its channel activity ([@B338]; [@B366]; [@B389]; [@B347]; [@B147]; [@B351]). Similarly, the ANT ligands, atractyloside and bongkrekic acid, modulate PTP opening ([@B175]). The function of PTP in apoptosis and necrosis ([@B303]) and as a potential therapeutic target for cancer, ischemia-reperfusion injury, and neurodegeneration were proposed ([@B289]).

### Osmotic matrix swelling and OMM rupture leading to non-specific release of inter-membrane proteins into the cytosol

This model proposes that a sudden increase in IMM permeability to solutes of low molecular weight leads to mitochondria swelling and rupture of the OMM, allowing the efflux of IMS proteins, such as Cyto *c*, to the cytosol ([@B128]). It has been suggested that matrix swelling and OMM rupture result from a defect in mitochondrial ATP/ADP exchange due to VDAC1 closure, as a result, for example, of removal of a normal growth factor or exposure to G3139 (Model B, **Figure [4](#F4){ref-type="fig"}**; [@B393], [@B394]; [@B224]). Several studies, however, demonstrated that Cyto *c* release preceded membrane potential (Δψ~m~) loss in cerebellar granule neurons undergoing apoptotic death and was not accompanied by mitochondrial swelling or OMM rupture ([@B10]; [@B116]; [@B413]).

### Bax oligomers constitute the OMM cytochrome *c*-conducting channel

A third proposed mechanism for Cyto *c* release suggests that oligomeric Bax forms the Cyto *c*-conducting channel in the OMM (Model C, **Figure [4](#F4){ref-type="fig"}**; [@B15], [@B16]; [@B124]; [@B438]; [@B216]; [@B305]). Upon apoptosis induction with STS or UV irradiation, Bax became associated with mitochondria as a large oligomer/complex of 96--260 kDa. While tBid enhances oligomerization of Bax ([@B236]), Bcl-2 prevented Bax oligomerization and insertion into the mitochondrial membrane. Several studies, however, showed that apoptosis can be induced in the absence of Bax ([@B232]; [@B264]; [@B405]), suggesting that the protein is not obligatory for apoptosis induction and that other mechanisms exist.

### Bax and bak oligomers form pores for pro-apoptotic factor efflux during apoptosis

The appearance of a channel formed by Bax and Bak hetero-oligomers upon apoptotic insult enabling efflux of pro-apoptotic effectors has been suggested (Model D, **Figure [4](#F4){ref-type="fig"}**; [@B160]; [@B116]; [@B410], [@B411]; [@B13]). tBid was proposed to activate the generation of Bax and Bak complexes up to 500 kDa ([@B371]). At the same time, anti-apoptotic proteins, such as Bcl-2 and Bcl-xL, were shown to protect cells from apoptosis via a blockage of the Bax--Bak interaction, subsequently preventing Cyto *c* release ([@B261]; [@B122]).

### Mitochondrial apoptosis-induced channel as a pathway for cytochrome *c* release

Mitochondrial apoptosis-induced channel (MAC), a supra-molecular high-conductance channel in the OMM, is thought to assemble during early apoptosis and serve as the Cyto *c* release channel that is regulated by Bcl-2 family members ([@B162]; [@B251], [@B250]; [@B103], [@B104],[@B105]; Model E, **Figure [4](#F4){ref-type="fig"}**). The complete molecular identity of MAC is unknown. Recently, it was proposed that Bax is an essential constituent of MAC in some systems, as the electrophysiological characteristics of MAC are very similar to those of Bax channels, while depletion of Bax significantly diminishes MAC activity ([@B252]).

### Hetero-oligomers composed of VDAC1 and bax form the apoptotic protein release channel

The formation of hetero-oligomers composed of VDAC1 and Bax were also proposed as a mechanism for Cyto *c* efflux (Model F, **Figure [4](#F4){ref-type="fig"}**; [@B340]; [@B341]; [@B27]). It was found that recombinant Bax induced permeability in liposomes containing VDAC, implying that VDAC can induce membrane permeability in the presence of Bax ([@B341]). In addition, intracellular microinjection of anti-VDAC antibodies prevented Bax-induced Cyto *c* release ([@B339]). Electrophysiological studies of Bax and VDAC in PLB revealed that when combined, single-channel conductance rises by factors of 4 and 10 over values attained with VDAC and Bax channels alone, respectively ([@B27]). Moreover, HK-I and HK-II compete with Bax for interaction with VDAC1 ([@B284]). It was also demonstrated that siRNA-mediated down-expression of VDAC1 strongly suppressed cisplatin-induced activation of Bax ([@B373]). Finally, another version of this model suggests that oligomeric VDAC is the prime Cyto *c* release channel and that its pore is regulated by Bax ([@B101]).

### Ceramides and the release of cytochrome *c*

A self-assembled ceramide-based lipid channel that forms in the OMM was suggested as being the Cyto *c* release pathway (Model G, **Figure [4](#F4){ref-type="fig"}**; [@B359]; [@B364]). Ceramides were postulated to form a pore in the OMM with a diameter large enough to accommodate Cyto *c* ([@B358]; [@B359]; [@B364]). An alternative mechanism proposes that ceramides promote the dissociation of Cyto *c* by altering IMM lipid microdomains ([@B432]). Another proposal suggest that ceramides and cholesterol both affect membrane microenvironments so as to favor Bax activation ([@B47]; [@B274]), with translocation to mitochondria fostering propagation of the apoptotic cascade ([@B249]).

### VDAC1 oligomerization and release of cytochrome *c*

In a model describing Cyto *c* release developed in our group, it is proposed that mitochondrial pore formation during apoptosis involves the assembly of homo-oligomers of VDAC1 (Model H, **Figure [4](#F4){ref-type="fig"}**; [@B436]; [@B351], [@B343]; [@B1]). This model is based on a VDAC1 diameter pore (2.5--3.0 nm; [@B35]) being large enough for the movement of nucleotides and small molecules but too small to allow passage of a folded protein, like Cyto *c*. Thus, a model in which Cyto *c* release takes place through the formation of large protein-conducting channel within a VDAC1 homo-oligomer or in a hetero-oligomer containing VDAC1 and pro-apoptotic proteins formed by oligomerization of VDAC1 is offered ([@B436]; [@B351], [@B343]; [@B1]). Substantial evidence for the formation of higher ordered VDAC1-containing complexes exists (see VDAC1 Oligomerization and Function).

Recently, it has been demonstrated that VDAC1 undergoes oligomerization in response to apoptotic stimuli, with VDAC1 oligomerization being enhanced up to 20-fold, as revealed by chemical cross-linking, or directly monitored in living cells using bioluminescence resonance energy transfer (BRET; [@B343]; [@B196]). Enhancement of VDAC oligomerization was obtained regardless of the cell type or apoptosis inducer used, including STS, curcumin, As~2~O~3~, etoposide, cisplatin, selenite, TNF-α, H~2~O~2~, or UV, all affecting mitochondria yet acting through different mechanisms ([@B196]; **Figure [5](#F5){ref-type="fig"}**). Conversely, the apoptosis inhibitor, DIDS, prevented STS-induced VDAC1 oligomerization and apoptosis ([@B343]; [@B196]). Moreover, VDAC1 over-expression resulted in VDAC1 oligomerization and apoptosis in the absence of any apoptosis stimuli ([@B343]). Furthermore, it was demonstrated that in cells expressing a VDAC1 dimeric fusion protein comprising wild type and the RuR-insensitive E72Q-mutated VDAC1 showed no protection against STS-induced apoptosis. This dominant-negative VDAC1 mutant reveals oligomeric VDAC1 to be the active unit in mitochondria-mediated apoptosis ([@B240]).

![**Apoptosis induction and VDAC1 oligomerization.** VDAC1 oligomerization as induced by apoptosis inducers and revealed by EGS-based cross-linking. HeLa cells were incubated for 16 h with STS (0.2 μM) or selenite (8 μM), as described previously ([@B196]), washed with PBS and incubated with EGS (300 μM) at 30^°^C for 10 min, followed by SDS-PAGE (10% acrylamide) and Western blotting using anti-VDAC1 antibodies. VDAC1 monomers, dimers, trimers, tetramers, and multimers are indicated. The arrow indicates an anti-VDAC1 antibody-labeled protein band migrating below the position of monomeric VDAC1. The positions of molecular weight protein standards are also provided.](fonc-02-00164-g005){#F5}

The molecular mechanisms triggering VDAC1 oligomerization upon apoptosis induction remain unknown. Post-translational modification of VDAC1, such as phosphorylation ([@B197]) or oxidation, may modulate its oligomeric state. The involvement of lipids has been suggested recently ([@B44]). The anionic lipid, phosphatidylglycerol (PG), was found to significantly enhance VDAC1 oligomerization in the membrane, whereas CL disrupts VDAC1 supra-molecular assemblies. Interestingly, during apoptosis, the level of PG in mitochondria increases, whereas that of CL decreases ([@B44]). Another proposed mechanism involves Cyto *c* detachment from its binding site, namely CL at the IMM. Apoptotic signals leading to the oxidation of CL and dissociation of Cyto *c* from the lipid ([@B279]), together with our finding that VDAC1 oligomerization is highly encouraged by Cyto *c* ([@B436]), support a scenario whereby unbound Cyto *c* promotes VDAC oligomerization, Cyto *c* release and subsequent apoptosis.

Clearly, a more complete understanding of the mechanisms underlying VDAC1 oligomer assembly and its role in Cyto *c*release will require additional study. Indeed, the multiple pathways and mechanisms of Cyto *c* release presented here may co-exist within a single model of cell death, depending on the cell type and the nature of the stimulus ([@B151]; [@B136]).

CANCER METABOLISM, HEXOKINASE, AND VDAC
=======================================

In recent years, a substantial body of evidence has accumulated indicating a correlation between alterations in cell metabolism and cancer formation. Cancer cells undergo significant metabolic adaptation to fuel cell growth and division ([@B137]; [@B172]; [@B206]). Malignant cancer cells typically display high rates of glycolysis even when fully oxygenated and are subject to suppressed mitochondrial respiration, despite the fact that glycolysis is a less energy-efficient pathway, a phenomenon known as the "Warburg effect" ([@B137]; [@B172]; [@B206]). The Warburg effect likely provides the vast majority of cancerous tumors with a number of benefits in the form of precursors for the biosynthesis of nucleic acids, phospholipids, fatty acids, cholesterol, and porphyrins. A second advantage of the Warburg effect is its likely involvement in both tumor protection and invasion. Tumor cells produce lactic acid via glycolysis and transport it out of the cell, leading to increased acidity of the closed microenvironment, generating a low pH "coat." This is proposed to protect tumors against attack by the immune system while inducing negative effects on normal surrounding cells, aiding in preparing the surrounding tissues for invasion. Additionally, the Warburg effect also assures longer tumor survival time if oxygen becomes limiting ([@B172]). Moreover, cancer-associated abnormalities in glucose metabolism enhance cellular resistance to apoptosis, with mitochondria playing a key role in this process ([@B126]; [@B213]; [@B255]; [@B133]; [@B152]). Finally, mitochondria have been found to playa role in cellular re-programming from the catabolic to the anabolic modes ([@B126]; [@B213]; [@B255]; [@B152]), with such metabolic flexibility and cellular hierarchy being crucial in metastatic cancer ([@B42]).

Such metabolic re-programming of cancer cells includes marked over-expression of mitochondrial-bound HK isoforms, considered as the rate-limiting enzyme of glycolysis and serving as the biochemical gate of this pathway ([@B288]; [@B253]; [@B286]; [@B346]). HK interacts with VDAC1 at the OMM and forms the main interface between mitochondria and the cytosol. VDAC1 contributes to cancer metabolism via transport of various metabolites, mediating ATP/ADP exchange across the OMM and is, therefore, defined as the "food channel." HK, by association with VDAC1, gains direct access to mitochondrial ATP, reaching VDAC1 via the ANT in the IMM, allowing it to phosphorylate and "trap" any incoming glucose ([@B287]). With this direct coupling of mitochondrially generated ATP to incoming glucose via VDAC1-bound HK, mitochondria regulate glycolytic flux with that of the tricarboxylic acid (TCA) cycle and ATP synthase to balance the energy requirements of the tumor cell with biochemical requirements for metabolites (i.e., the anaplerotic and cataplerotic pathways, respectively) or metabolite precursors that are required by the tumor ([@B288]; [@B253]; [@B286]; [@B346]). Thus, both the glycolytic pathway and other seminal metabolic pathways, like the pentose phosphate shunt, are regulated via the energy-coupling resulting from the formation of the VDAC1-bound HK complex. As part of a system that impacts cell growth, the VDAC1--HK complex represents a remarkable target for cancer therapy (see The Interaction of VDAC1 with Hexokinase Regulates Cell Bioenergetics and Apoptosis).

VDAC1 ASSOCIATION WITH PROTEINS AND CANCER
==========================================

The localization of VDAC1 at the OMM provides structural and functional anchoring sites for a diverse set of cytosolic proteins that together with VDAC1 mediate metabolic and signaling cross-talk between cytosol and mitochondria (**Table [1](#T1){ref-type="table"}**). VDAC1 displays binding sites for glycerol kinase ([@B7]), HK ([@B22]; [@B283]; [@B3]; [@B154]; [@B344]; [@B19]), creatine kinase ([@B327]), C-Raf kinase ([@B226]), ANT ([@B404]), the peripheral benzodiazepine receptor \[also known as translocator protein (TSPO); [@B397]\], tubulin ([@B319]), the dynein light chain, mtHSP70, the ORDIC channel, GAPDH ([@B350]), actin ([@B420]), and gelsolin ([@B215]), as well as Bcl-2 family members ([@B351]; [@B6]; [@B235]). Interaction with apoptosis-regulating proteins, such as HK and Bcl-2 family members, make VDAC1 a key protein in apoptosis regulation ([@B389]). Here, we focus on those VDAC1-interacting proteins showing modified levels of expression in cancer cells.

###### 

Modulation of VDAC conductance and mitochondrial-mediated apoptosis by VDAC-associated proteins.

  Protein                                  VDAC conductance                    PTP opening            Cyto *c* release                   Cell death                            Interaction demonstrated by
  ---------------------------------------- ----------------------------------- ---------------------- ---------------------------------- ------------------------------------- --------------------------------------------------------------------------------------------------------
  GAPDH                                    ND                                  Activation ([@B43])    Activation ([@B377])               Activation ([@B43])                   Affinity-chromatography ([@B350])
  Bcl2                                     Reduction ([@B18])                  ND                     Inhibition ([@B183])               Protection ([@B91]; [@B92])           ND
  Bax^[a](#T1fn01){ref-type="fn"}^         Increase ([@B340],[@B6]; [@B27])    Activation ([@B297])   Increase ([@B340],[@B9]; [@B14])   Induction ([@B339]; [@B284])          Liposome ([@B338]); immunoprecipitation ([@B340])
  HK-I                                     Reduction ([@B22]; [@B435])         Inhibition ([@B22])    Inhibition ([@B22]; [@B3])         Protection ([@B22]; [@B435]; [@B3])   SPR with VDAC1 peptides ([@B19]); site directed mutagenesis ([@B435]; [@B3]; [@B19])
  HK-II                                    ND                                  ND                     Inhibition ([@B284])               Protection ([@B284])                  Site directed mutagenesis ([@B19])
  hGelsolin^[b](#T1fn02){ref-type="fn"}^   Inhibition ([@B215])                Activation ([@B215])   Inhibition ([@B215]; [@B299])      Inhibition ([@B215])                  Immunoprecipitation ([@B215])
  Bcl-Xl                                   Reduction ([@B340],[@B8]; [@B17])   ND                     Inhibition ([@B340])               Protection ([@B91]; [@B92])           Immunoprecipitation ([@B340]); reconstituted membranes ([@B338]); NMR ([@B245])
  Bak                                      ND                                  ND                     Increase ([@B340])                 Induction ([@B373])                   Reconstituted membranes ([@B338])
  ANT                                      ND                                  Activation ([@B401])   Increase ([@B57])                  Induction ([@B82])                    Co-purification ([@B6],[@B5]); co-immunoprecipitation ([@B68]); purified proteins interaction ([@B64])
  CK                                       ND                                  ND                     ND                                 ND                                    SPR, co-purification ([@B45])
  Actin                                    Modulates gating ([@B420])                                                                    Induction ([@B376])                   SPR ([@B310]); reconstituted membranes ([@B420])
  Tubulin                                  Reduction ([@B319])                 ND                     ND                                 Inhibition ([@B309])                  Immunoprecipitation ([@B70])
  tBid                                     Reduction ([@B314])                 Activation ([@B96])    Induction ([@B96]; [@B61])         Induction ([@B438])                   Reconstituted membranes ([@B314])
  TSPO                                     ND                                  Activation ([@B285])   ND                                 ND                                    Co-purification ([@B256])
  eNOS                                     ND                                  ND                     ND                                 ND                                    Co-immunoprecipitation ([@B369])
  mtHSP70                                  Reduction ([@B329])                 Inhibition ([@B176])   ND                                 Inhibition                            Two-hybrid system ([@B329])
  Dynein light chain                       Increase ([@B329])                  ND                     ND                                 ND                                    Two-hybrid system ([@B329])

*Bax oligomerizes with VDAC ([@B4])*.

Ca^2+^-dependent binding to VDAC.

THE INTERACTION OF VDAC1 WITH HEXOKINASE REGULATES CELL BIOENERGETICS AND APOPTOSIS
-----------------------------------------------------------------------------------

### HK expression and bioenergetics regulation in cancer cells

One of the signature phenotypes of highly malignant, poorly differentiated tumors is their high rate of glycolysis, leading to enhanced lactate generation ([@B55]). This property is frequently dependent on the marked over-expression of VDAC1-bound HK ([@B313]; [@B157]; [@B62]; [@B288]; see Cancer Metabolism, Hexokinase and VDAC). HK thus lies at the apex of the glycolytic pathway that provides the metabolic intermediates required by the biosynthetic pathways on which a transformed cell places such heavy demand ([@B286]; [@B254]).

Hexokinase catalyzes the rate-limiting step in glycolysis, the ATP-dependent phosphorylation of glucose to G-6-P. The mitochondria bound-isoforms, HK-I and HK-II, were found to be over-expressed in many cancers, including colon, prostate, lymphoma, glioma, gastric adenomas, carcinomas, and breast cancers ([@B157]; [@B62]; [@B254]). The elevated levels of mitochondria-bound HK in cancer cells is thus suggested to play a pivotal role in promoting cell growth and survival in rapidly growing, highly glycolytic tumors and in protecting against mitochondria-mediated cell death ([@B253]). The association/dissociation of HK with/from VDAC1 and the switching of VDAC1 between an "open" and a "closed" state regulate cross-talk between mitochondria and the cytosol ([@B351], [@B346]). This control is important in maintaining the mitochondria respiration and glycolysis equilibrium at the heart of the energetic and metabolic homeostasis of the cancer cell. Cancer cell, however, possess an escape mechanism that intervenes when G-6-P accumulates and dissociates HK from VDAC ([@B22]).

### VDAC1 is the mitochondrial binding site of HK

The interaction of HK with the mitochondria, and specifically with VDAC1, has shifted our view of HK as predominantly fulfilling a metabolic role to one of regulation of apoptotic responsiveness of the cell, making the VDAC1--HK complex a target for therapeutic purposes ([@B284]; [@B22]; [@B283]; [@B351], [@B344], [@B352]; [@B3]; [@B154]; [@B282]; [@B19]).

The interaction between HK-I and VDAC1 was first demonstrated in a reconstituted system where HK-I decreased the channel conductance of VDAC1, an effect that was reversed by G-6-P, shown to detach HK from isolated mitochondria ([@B22]). The interaction between HK-I and VDAC1 was again demonstrated by co-immunoprecipitation ([@B343]). The co-localization of HK-I with each of the three isoforms of VDAC1 was demonstrated using two-color stimulated emission depletion (STED) microscopy ([@B270]). The HK-I--VDAC1 interaction can be abrogated upon mutagenesis of a single VDAC1 residue (Glu73, Glu202, or Glu65), resulting in an elimination of HK-mediated protection against apoptosis and channel closure ([@B435]; [@B3]). N-terminally truncated VDAC1 is incapable of binding HK ([@B1]) or Bcl-xL ([@B17]). Moreover, when the N-terminal region α-helix structure in VDAC1 was perturbed, the binding of HK was reduced ([@B143]). It was proposed that the N-terminal region of HK-I is inserted into the channel pore, where it interacts with the N-terminal region of VDAC1 ([@B312]). It should be noted that there is strong residue conservation between the HK-I and HK-II N-termini, and that such conservation is not shared by the other two non-bound mitochondrial isoforms, HK-III and HK-IV.

The VDAC1--HK interaction was shown to be negatively regulated by phosphorylation, when GSK3β is up-regulated ([@B283]). Finally, VDAC1-based peptides were found to interact with purified HK and when expressed in cells over-expressing HK, prevented the anti-apoptotic activity of HK ([@B19]).

### HK-linked protection against cell death is mediated via interaction with VDAC1

*In vitro* and *in vivo* studies have shown that elevated levels of mitochondria-bound HK in cancer cells also protect against mitochondria-mediated apoptosis via direct interaction with VDAC1.

Mitochondrially associated HK has been shown to protect HeLa and HEK cells from entering apoptosis ([@B62]). This protection was related to a blockade of the interaction of the pro-apoptotic protein, Bax, with VDAC1 ([@B62]). Moreover, over-expression of HK-I or HK-II in tumor-derived cell lines suppressed STS-induced Cyto *c* release and apoptosis ([@B22]; [@B435]; [@B19]). A decrease in apoptosis and an increase in cell proliferation have also been reported to be induced by HK-II expression in the NIH-3T3 ([@B127]) and rat 1a cell lines ([@B157]). Importantly, mutagenesis studies revealed that single mutations or N-terminal truncation in VDAC1 prevented HK-I-mediated protection against apoptosis and channel closure in a reconstituted membrane system ([@B435]; [@B3], [@B1]; [@B352]). In addition, binding of HK-II to mitochondria inhibits Bax-induced Cyto *c* release and apoptosis ([@B284]). HK binding to VDAC1 is regulated by protein kinases, notably GSK-3β ([@B283]) and protein kinase C (PKC; [@B282]), as well as by the cholesterol content of the OMM ([@B282]).

### HK interaction with VDAC1, advantages to cancer cells

Several mechanisms by which HK binding to VDAC1 protects against apoptosis and promotes cell survival can be considered. These include controlling energy and metabolic homeostasis, as well as preventing VDAC1-mediated Cyto *c* release and shielding VDAC1 from pro-apoptotic factor binding, thus offering the tumor cell protection from cell death in a synergic manner. The advantages to cancer cells of HK binding to VDAC1 include:

***Energy and metabolite production and access*.** Hexokinase bound to VDAC1 provides cells with metabolic advantages, allowing enhanced cell growth ([@B286]). Anchoring of HK to VDAC1 offers the enzyme direct access to mitochondrial sources of ATP and greater affinity for Mg^2+^-ATP ([@B65]; [@B287]). HK bound to the cytosolic face of VDAC1 acts as a gate, regulating the traffic of various metabolites through the VDAC1 ([@B22]). In addition, VDAC1-bound HK is less sensitive to inhibition by its product, G-6-P ([@B22]), thus avoiding product inhibition. The HK--VDAC1 interaction increases energy and metabolite production of the high energy-demanding cancer cells, allowing for maintenance of a high glycolytic flux rate in tumors ([@B22]).

***VDAC1-bound HK acts as an anti-apoptotic protein*.** Accumulated evidence demonstrated that HK-I and HK-II also function as anti-apoptotic proteins when bound to VDAC1, while their detachment enabled activation of apoptosis ([@B284], [@B283]; [@B22]; [@B351], [@B344], [@B352]; [@B3]; [@B154]; [@B282]; [@B19]). Disruption of HK binding to VDAC1 by mutation in VDAC1 or by addition of VDAC1-based peptides decreased the survival of cancer cells ([@B19]).

Hexokinase interaction with VDAC1 protects against activation of apoptosis by Bax or Bak ([@B284]; [@B244]; [@B282]). The detachment of HK-II from the mitochondria was found to markedly potentiate the onset of caspase-2-induced mitochondrial damage ([@B354]).

***Regulation of ROS production by HK*.** Reactive oxygen species act as second messengers in cell signaling and are essential for multiple biological processes in normal cells. However, ROS can also provoke damage to multiple cellular organelles and processes ([@B20]). ROS production is usually increased in cancer cells due to oncogene activation ([@B441]; see VDAC1 Function in ROS Release, ROS-mediated Apoptosis and Interaction with NO). Mitochondria-associated HK was shown to reduce mitochondrial ROS generation ([@B100]), with HK-I and HK-II reducing intracellular levels of ROS ([@B370]). Moreover, expression of both HK-I and HK-II was found to protect against oxidant-induced cell death ([@B9]; [@B62]). Thus, detachment of HK from VDAC1 could lead to increased ROS generation and release to the cytoplasm, thereby activating cell death.

***Stabilization of both HK and VDAC1*.** VDAC1, containing an odd number of β-strands, presents conformational intrinsic instability within the first four β-strands (β1--4), relative to other VDAC1 regions ([@B35]).

*In silico* studies of the VDAC1--HK-I interaction predicates that both proteins attain a more stable state through protein--protein interaction ([@B312]). It is proposed that upon binding with the N-terminal helix of HK-I, VDAC1 acquires higher stability via the formation of a network of chemical bonds both due to direct protein--protein contacts and to hydrogen bonds mediated by an ATP molecule and an Mg^2+^ ion ([@B312]).

***Increased synthesis and uptake of cholesterol*.** Cancer cells have been shown to exhibit a 2- to 10-fold increase in mitochondrial cholesterol content, in comparison to liver mitochondria ([@B25]). It has been proposed that the increased binding of HK to the mitochondria of cancer cells may play a role in mediating increased synthesis and uptake of cholesterol into the mitochondria of cancer cells ([@B282]).

### Disruption of the HK--VDAC interaction as an approach to cancer therapy

If one considers the metabolic importance of both VDAC1 and HK, the role that HK fulfills in promoting tumor cell survival and the function of the HK--VDAC1 interaction in regulating apoptosis, as well as other functions as presented above, then disruption of the HK--VDAC1 complex represents an attractive target for cancer therapy and may form the basis for novel anti-cancer drugs. Indeed, several different compounds have been employed to disrupt the HK--VDAC1 association, resulting in apoptotic cell death. These include peptides corresponding to the amino terminus of both HK-I ([@B140]) and HK-II ([@B284]), clotrimazole ([@B291]; [@B284]; [@B344]) and a cell-permeable HK-II-based peptide ([@B243]). Methyl jasmonate (a plant-derived stress hormone) binds to and detaches mitochondria-bound HK from several cancer cell types ([@B154]). HK detachment can be visualized using HK--GFP. Cell expression of HK-I--GFP showed punctuated distribution that co-localized with MitoTracker Red (**Figure [6](#F6){ref-type="fig"}**), suggesting a mitochondrial localization. The induction of apoptosis by STS resulted in HK--I-GFP detachment, as reflected by the diffuse fluorescence seen (**Figure [6](#F6){ref-type="fig"}**).

![**Detachment of mitochondrial-bound HK-I-GFP induced by STS.** To demonstrate HK-I binding to mitochondria (i.e., VDAC) as well as detachment, a HK-I--GFP fusion protein was expressed in HEK--T cells. Confocal fluorescence microscopy showed that in control cells expressing HK-I--GFP, the fluorescence is punctuated, as expected for mitochondrial distribution. On the other hand, induction of apoptosis by STS detaches mitochondrial-bound HK-I--GFP. HEK--T cells were transfected to express HK-I--GFP and after 48 h were exposed to STS (0.8 μM), stained with 25 nM of the mitochondrial marker MitoTracker Red and visualized with confocal microscopy. The punctuated HK-I--GFP fluorescence, originally co-localized with mitochondria (control), as also reflected in the co-localization with MitoTracker Red (Merge panel), was converted to diffuse labeling of the cytosol after exposure to STS. Images are representative microscopic fields from one of three similar experiments (scale bar = 5 μm).](fonc-02-00164-g006){#F6}

The small molecule alkylating agent, 3-bromopyruvic acid (3BP) was found to be phosphorylated by HK and to inhibit glycolytic rate in VX2 tumors ([@B203]). 3BP covalently modifies protein cysteine residues, resulting in rapid activity loss ([@B258]; [@B202]; [@B292]). In animal models, 3BP showed high efficacy against advanced stage malignant tumors by inhibiting both glycolysis and mitochondrial energy generation, possibly by interfering with the HK--VDAC1 complex ([@B42]). Thus, 3BP is proposed to target metabolism and blocks energy supplies. Other studies demonstrated the potential of 3BP as a potent anti-cancer agent in humans ([@B204]). Current knowledge related to 3BP and its promise as a future cancer therapeutic are the focus of a special 2012 issue of the Journal of Bioenergetics and Biomembranes (JOBB 44-1, 2012).

In conclusion, since VDAC1-bound HK is essential for tumor cells, conferring several advantages (see HK-linked Protection Against Cell Death is Mediated via Interaction with VDAC1), including protection against apoptotic events and promoting aerobic glycolysis, the detachment of HK from VDAC1 offers a novel therapeutic strategy to augment apoptosis, revert the hyper-glycolytic state and enhance the therapeutic efficacy of conventional chemotherapeutic agents.

MEMBERS OF THE Bcl-2 FAMILY OF PROTEINS INTERACT WITH VDAC
----------------------------------------------------------

The B cell lymphoma/leukemia-2 (Bcl-2) family of proteins plays an essential role in the control of apoptosis ([@B59]) at the interface with mitochondria. The Bcl-2 family consists of more than 20 pro-apoptotic (e.g., Bid, Bax, and Bak) and anti-apoptotic (e.g., Bcl-2 and Bcl-xL) members, all characterized by the presence of Bcl2 homology (BH) domains ([@B6]; [@B430]). Accordingly, these proteins can be sub-divided into three main groups, based on the regions of the BH domain they contain and their function, namely the multi-domain anti-apoptotic (Bcl-2, Bcl-xL, Bcl-w, Mcl-1, and Bfl-1/A1), the multi-domain pro-apoptotic \[Bcl-2-associated X protein (Bax) and Bak\], and the BH3-only pro-apoptotic (Bid, Bim, Bad, Bik, Noxa, PUMA, Bmf, and Hrk) proteins ([@B75]). The anti-apoptotic members of the Bcl-2-family contribute to tumor initiation, disease progression, and drug resistance ([@B263]; [@B6]). Indeed, enhanced expression of anti-apoptotic Bcl-2 family members was shown to be associated with the resistance of many tumors to chemotherapy ([@B332]; [@B6]). For example, in multiple studies, increased levels of Bcl-2, Bcl-xL, and Mcl-1 proteins were linked to survival of multiple myeloma cells and resistance to chemotherapy ([@B273]), while in most cases of chronic lymphocytic leukemia (CLL), elevated Bcl-2 mRNA and protein levels are noted ([@B388]).

The mechanism whereby Bcl2 family members control apoptosis is still not fully understood. However, it is well established that their activities involve controlling OMM permeability ([@B331]; [@B6]; [@B430]). Accumulated findings linked the activity of both anti-apoptotic and pro-apoptotic proteins to their association with VDAC ([@B341]; [@B337]; [@B366]; [@B334]; [@B387]; [@B245]; [@B373]; [@B18]). VDAC1 interacts with Bax, Bim, Bcl2, and Bcl-xL in isolated mitochondria and in reconstituted membrane systems ([@B337]; [@B314]; [@B245]; [@B17]). Purified C-terminally truncated Bcl2 and Bcl-xL interact with VDAC1 and reduced the channel conductance of wild type but not of certain mutated forms of VDAC1 ([@B18]; [@B17]) or N-terminally truncated VDAC ([@B1]; [@B17]). Similarly, both Bcl2 and Bcl-xL prevented apoptosis as induced by various stimuli in cells expressing wild type but not mutated VDAC1 ([@B1]; [@B18]; [@B17]). It was proposed that VDAC1 interacts with both Bax and Bcl-xL to form a tertiary complex ([@B334]). A direct interaction between Bcl-xL and VDAC1 was demonstrated by NMR ([@B245]). Interaction of the putative loop region of VDAC1 with Bcl-xL was proposed ([@B334]). Bcl-xL was also shown to affect VDAC oligomerization, as revealed by chemical cross-linking of micelle-bound VDAC, shifting the equilibrium of VDAC from the trimeric to the dimeric state ([@B245]). Furthermore, synthetic peptides corresponding to the VDAC1 N-terminal region and other cytosol-facing VDAC1 sequences bound Bcl2 and Bcl-xL ([@B334]; [@B1]; [@B352]; [@B18]; [@B17]). Such peptides, in cell-penetrating form or expressed in the cell, were able to suppress the anti-apoptotic activities of Bcl2 and Bcl-xL in cells ([@B1]; [@B18]; [@B17]). Thus, VDAC1-based peptides, targeting the anti-apoptotic activity of Bcl-xL and Bcl2, can serve as potential cancer therapeutics.

Bax and VDAC reconstituted into liposomes were shown to form a new channel, with a conductance 4--10 times larger than that of the individual proteins ([@B337]), and with such increase being prevented by Bcl-xL. The interaction of Bax and Bim with VDAC leads to Cyto *c* release, with Bcl-xL and anti-VDAC antibodies preventing this release ([@B339]). It has also been shown that Bid but not Bax modulates VDAC channel conductance ([@B314]).

In VDAC1-depleted cells, cisplatin-induced activation of Bax was inhibited ([@B373]), suggesting that VDAC1 is involved in Bax-mediated apoptosis. Furthermore, Bcl-2 and Bcl-xL blocked As~2~O~3~-induced VDAC dimerization ([@B443]). These results indicate that Bcl-2 family proteins regulate VDAC-mediated apoptosis and hence, the release of apoptogenic proteins from mitochondria.

VDAC AND THE TRANSLOCATOR PROTEIN
---------------------------------

Translocator protein is an 18-kDa integral membrane protein, originally identified as the peripheral benzodiazepine receptor or isoquinoline-binding protein ([@B208]), that is over-expressed in breast, prostate, colon, and brain cancer, with protein expression linked to cancer progression and poor survival rates ([@B29]). Like VDAC1, TSPO is located in the OMM and was proposed to activate PTP opening, leading to apoptosis ([@B228]; [@B397]; [@B355]). Interactions between TSPO and VDAC are thought to play a role in apoptosis ([@B139]; [@B228]; [@B397]). High-affinity ligand occupancy of TSPO was shown to attenuate anti-neoplastic agent-induced apoptosis ([@B214]). The observations that TSPO is involved in the generation of ROS and that TSPO association with VDAC may enhance ROS production prior to apoptotic induction, indirectly links both proteins ([@B153]; [@B395], [@B397]). Still, there is no direct evidence for a TSPO--VDAC1 interaction at the molecular level.

INTERACTION OF VDAC1 WITH AND REGULATION BY CYTOSKELETAL PROTEINS
-----------------------------------------------------------------

In cancer, morphogenic changes are required for high proliferative rates, the acquisition of inappropriate migratory patterns, and invasive characteristics ([@B168]). Alterations in the dynamics of the actin and tubulin components of the cytoskeleton are well-known consequences of signaling and the triggering of responses like apoptosis ([@B131]; [@B315]). Mitochondria are dynamic organelles that actively travel along the cytoskeleton within the cell. Within this framework, specific association of VDAC1 with tubulin was shown by co-immunoprecipitation ([@B70]) and by tubulin-induced VDAC1 closure ([@B318]). A model was proposed whereby the negatively charged C-terminus of tubulin penetrates into the positively charged VDAC1 pore, leading to decreased channel conductance ([@B319]). It was proposed that tubulin, VDAC1 and mitochondrial creatine kinase (MtCK) are members of a super complex that is structurally and functionally coupled to the ATP synthasome ([@B322]). Recent evidence indicates that the lipid composition of the membrane is capable of controlling tubulin--VDAC interactions, thus tuning VDAC sensitivity to blockage by tubulin ([@B316]). Similarly, it has been reported that tubulin--VDAC interactions can be regulated by varying the membrane surface charge ([@B164]). In a cellular model of cardiomyocyte physiology, the super complex presents a different composition, namely one in which tubulin is replaced by HK and MtCK is absent, infusing mitochondrially generated ATP into the glycolytic pathway and thereby contributing to the Warburg effect ([@B322]). Other proteins associated with cytoskeleton dynamics, such as gelsolin ([@B215]), adseverin or scinderin (SCIN; [@B262]), have been reported to associate with VDAC, with concomitant anti-apoptotic effects.

All of these VDAC1--protein interactions establish a new interplay between kinase signaling pathways, mitochondrial respiration, and the highly dynamic microtubule network characteristic of cancerogenesis and cell proliferation. VDAC1, as the common denominator in all the interactions described above, thus presents a single unique target for efforts addressing cell physiological, metabolic, and morphological aspects of cancer.

INTERACTION OF VDAC1 WITH VIRAL PROTEINS
----------------------------------------

Many viruses encode for proteins acting on mitochondria, in general, on VDAC1, in particular, or directly targeting proteins in the apoptotic pathway ([@B52], [@B53]; [@B125]; [@B184]; [@B400]). Other viruses influence apoptosis by mimicking Bcl-2 family proteins, changing their expression levels or directly interacting with Bcl-2 family proteins ([@B167]; [@B51]). HIV-1 offers an excellent example of neuronal and immunological-destructive apoptosis involving mitochondria ([@B367]; [@B293]). HIV-1 envelope proteins can trigger mitochondrial apoptosis, increasing cytosolic Ca^2+^, ROS, and transcriptional activation of p53, thus increasing the expression of pro-apoptotic proteins, such as Bax ([@B74]). The PB1-F2 protein of the influenza A virus, when localized in mitochondria, induces alteration of mitochondrial morphology, dissipation of the mitochondrial membrane potential, and cell death and has been reported to interact directly with VDAC ([@B437]; [@B99]). Hepatitis B virus (HBV) is another mitochondria-interacting virus ([@B53], [@B51]; [@B342]). The HBx protein is highly homologous to VDAC1 and is proposed to "poison" the homo-oligomeric state of VDAC1, creating hetero-oligomeric structures that induce permeability of the mitochondria, allowing Cyto *c* release ([@B363]; [@B300]; [@B351]; [@B155]; [@B182]). This action of HBx can result in the development of hepatocellular carcinomas ([@B300]). In infected liver cell lines, hepatic virus (HEV) not only induced up-regulation of VDAC expression in infected human hepatoma cell lines but also encouraged higher levels of VDAC oligomerization, leading to apoptosis ([@B266]).

VDAC1 EXPRESSION LEVELS IN HEALTHY AND CANCER CELLS
===================================================

In higher eukaryotes, VDAC1 is the most predominant isoform expressed. Several studies have shown that alterations in VDAC1 expression affect both the ability of cells to generate energy and their sensitivity to apoptosis-inducing reagents.

VDAC EXPRESSION LEVELS IN CANCERS AND ENHANCEMENT BY PRO-APOPTOTIC DRUGS
------------------------------------------------------------------------

Several studies have demonstrated remarkable differences in the expression levels of VDACs between tumor cells and normal tissues. VDAC1 expression in several cancer cell lines was higher than in the control fibroblast cell line ([@B356], [@B357]). NSCLC cells specifically exhibited high expression levels of VDAC1. This was shown to directly correlate with poor outcome in early stage NSCLC, thus establishing an association with aggressive tumor behavior ([@B159]). In addition, in several melanoma and prostate cancer cell lines, a correlation between levels of VDAC1 expression and induction of Cyto *c* release by G3139 was demonstrated ([@B217]). In a proteomic analysis of aging-related proteins in human normal colon epithelial tissues, significant up-regulation of 19 proteins was noted, including VDAC1 and VDAC2 ([@B231]).

Several cancer treatments were found to enhance expression of VDAC. Up-regulation of VDAC1 expression was observed in three different acute lymphoblastic leukemia (ALL) cell lines (697, Sup-B15, and RS4;11) following prednisolone treatment, an observation that can be explored for predicting eventual outcome in childhood ALL ([@B190]). VDAC1 over-expression was observed in a cisplatin-sensitive cervix squamous cell carcinoma cell line (A431) when exposed to cisplatin, while in a cisplatin-resistant cell line (A431/Pt), the treatment resulted in down-regulation of VDAC1 ([@B73]). Up-regulation of VDAC has been reported upon UV irradiation of apoptosis-sensitive cells ([@B402]). When A375 human malignant melanoma cells were treated with the tyrosinase inhibitor, arbutin, a potential anti-tumor agent ([@B269]), VDAC1 expression level was found to be up-regulated ([@B80]). In addition, ROS was found to induce up-regulation of VDAC that could be prevented by the ROS chelator, epigallocatechin ([@B192]).

The relationship between VDAC1 expression levels and sensitivity to various treatments was presented in several studies. The PC3 and DU145 prostate cancer cell lines are relatively resistance to apoptosis as induced by G3139 and were found to express less VDAC than did G3139-sensitive LNCaP cells ([@B217]). Similarly, reducing VDAC1 expression by siRNA efficiently prevented cisplatin-induced apoptosis and Bax activation in NSCLC ([@B373]), attenuated endostatin-induced apoptosis ([@B433]) and inhibited selenite-induced PTP opening ([@B384]). The anti-cancer activity of furanonaphthoquinones (FNQs) was increased upon VDAC1 over-expression and decreased upon silencing of VDAC1 expression by siRNA ([@B357]).

Finally, it has also been shown that the CD45 expression is accompanied by elevated VDAC1 expression in myeloma cells sensitized to a diverse set of apoptotic stimuli via the mitochondrial pathways ([@B234]).

SILENCING OF VDAC1 EXPRESSION
-----------------------------

Among the complex array of genetic changes accompanying cancer development, all cancerous cells develop altered metabolism, with VDAC1 and HK playing important functions in this metabolic reprograming (see The Interaction of VDAC1 with Hexokinase Regulates Cell Bioenergetics and Apoptosis). VDAC1 contributes to cancer metabolism via transport of various metabolites, mediating ATP/ADP exchange across the OMM and by the binding and channeling of mitochondrial ATP directly to HK (see Cancer Metabolism, Hexokinase and VDAC). The importance of VDAC1 for cancer cells is further reflected in the findings that silencing VDAC1 expression reduced cellular ATP levels and cell growth ([@B2]). Furthermore, when HeLa cervical cancer cells stably expressing shRNA directed against hVDAC1 were injected into nude mice, the development of a solid tumor was inhibited ([@B207]). It has also been shown that VDAC1 silencing potentiates H~2~O~2~-induced apoptosis and impairs mitochondrial Ca^2+^ loading, while silencing VDAC2 had the opposite effects ([@B117]). Together, these findings indicate that over-expression of VDAC1 in cancer cells could contribute to the high glycolytic phenotype seen.

ENHANCEMENT OF VDAC1 EXPRESSION, OLIGOMERIZATION AND APOPTOSIS INDUCTION
------------------------------------------------------------------------

As presented above (see VDAC Expression Levels in Cancers and Enhancement by Pro-apoptotic Drugs), the expression level of VDAC1 serves as a crucial factor in the process of mitochondria-mediated apoptosis as induced by various means. Indeed, over-expression of VDAC from different sources, such as yeast, rice, fish, mice, and humans, was found to induce apoptosis ([@B150]; [@B435]; [@B145]; [@B237]). Over-expression of murine (m) VDAC1 or rat (r) VDAC1 in U-937 cells resulted in apoptotic cell death ([@B435]). Moreover, over-expression of rice VDAC induced apoptosis ([@B150]) that was blocked by Bcl-2 and the VDAC channel inhibitor, DIDS. Similar results were obtained following transfection of fish cells to express *Paralichthys olivaceus* VDAC ([@B237]). Over-expression of VDAC1 causes depolarization of the IMM and activation of the PTP ([@B115]; [@B384]).

The mechanism underlying cell death induced by VDAC1 over-expression is not fully understood. However, recent studies demonstrated that VDAC1 over-expression is accompanying by its oligomerization ([@B436]; [@B155]; [@B182]; [@B245]; [@B343],[@B344]; [@B440]; [@B196]). VDAC1 has been shown to form different oligomeric states, namely monomers, dimers, trimers, tetramers, hexamers, and higher-order oligomers (see VDAC1 Oligomerization and Function). Moreover, the supra-molecular assembly of VDAC1 in cultured cells is highly enhanced upon apoptosis induction, supporting the involvement of VDAC1 oligomerization in Cyto *c* release and thus, in apoptosis ([@B344]; [@B196]). Moreover, VDAC1 over-expression resulted in its oligomerization in the absence of any apoptosis stimuli ([@B344]). It should be noted that apoptosis induced by VDAC1 over-expression shares common features with apoptosis induced by other stimuli (e.g., STS, H~2~O~2~), as is the case for inhibition by RuR, Bcl2, HK-I over-expression, or DIDS, all agents that interact with VDAC1 ([@B351]). Finally, HEV-infected human hepatoma cells showed enhanced VDAC expression, leading to VDAC oligomerization and apoptosis ([@B266]).

Thus, the over-expression of VDAC1, as induced by drugs, such as arbutin, prednisolone, or cisplatin, or by viral proteins or UV irradiation, as well as the correlation between drug effectiveness and VDAC expression, suggest that the anti-cancer activities of these drugs is associated with VDAC levels. This is further supported by the finding that cisplatin-induced apoptosis is inhibited in cells silenced for VDAC1 expression ([@B115]; [@B384]). In addition, endostatin-induced apoptosis was decreased upon silencing VDAC1 expression, and enhanced by over-expression of VDAC1 ([@B433]). We thus propose that the high levels of VDAC1 promote its oligomerization, leading to apoptosis ([@B344]; [@B196]). Accordingly, anti-cancer strategies that specifically up-regulate VDAC1 levels in cancer cells may activate the mitochondrial apoptotic pathway, with concomitant benefit to the patient.

VDAC1 FUNCTION IN ROS RELEASE, ROS-MEDIATED APOPTOSIS AND INTERACTION WITH NO
=============================================================================

MITOCHONDRIA, ROS, AND OXIDATIVE STRESS
---------------------------------------

Reactive oxygen species serve important roles in diverse events, such as cellular proliferation, differentiation, and migration. It is now accepted that cellular "redox" signaling is involved in regulating normal processes and disease progression, including angio- genesis, oxidative stress, aging, and cancer. Cellular levels of ROS are linked to anti-tumor immunity, the oxidative tumor microenvironment, proliferation, and death of cancer cells ([@B246]).

Cancer cells exhibit high basal levels of oxidative stress due to the activation of oncogenes, loss of tumor suppressors, and the effects of the tumor microenvironment ([@B66]). Hypoxia, a characteristic of most solid tumor microenvironments, causes a progressive elevation in mitochondrial ROS production (chronic ROS) which over time leads to the stabilization of cells via increased HIF-2α expression, which serve as signaling molecules that activate the transcription of genes involved in cellular hypoxic adaptation ([@B169]). It is becoming apparent that hypoxia enables cells to survive with sustained levels of elevated ROS. However, the increased oxidant concentrations associated with cellular transformation promote tumorigenicity through signaling but can also damage DNA, proteins, and lipids. Indeed, promoting oxidative stress in cancer cells selectively kills several cancer cell lines ([@B385]; [@B272]; [@B301]).

Reactive oxygen species are mainly produced in the mitochondria as by-products of respiratory chain reactions, with 1--5% of the oxygen consumed by mitochondria in human cells being converted to ROS, such as superoxide anions ($\text{O}_{2}^{- \cdot}$), H~2~O~2~, and hydroxyl radicals ([@B267]). Oxidative stress results when production of ROS exceeds the capacity of mitochondrial and cellular anti-oxidant defenses to remove these toxic species. Indeed, to combat harmful ROS, cells possess several anti-oxidant defense mechanisms, including catalytic removal of reactive species by enzymes like superoxide dismutase (SOD), catalase, and peroxidase ([@B28]; **Figure [6](#F6){ref-type="fig"}**). However, about 1% of the ROS escapes elimination and cause oxidative cellular damage. The rules governing ROS transport via the OMM and control of this process, as well as the molecular mechanism of ROS activating VDAC to release Cyto *c*, are not clear.

VDAC1 MEDIATES ROS RELEASE FROM THE MITOCHONDRIA
------------------------------------------------

Since ROS are generated in the mitochondria, they can attack the mitochondria directly and, when released to the cytosol, can attack and modify DNA, lipids, and proteins, thus affecting cell survival ([@B278]). This requires ROS release from the mitochondria to the cytosol, namely, crossing the OMM. VDAC1 in the OMM may serve as the major gateway for molecules exiting the IMS. Indeed, VDAC1 has been proposed to mediate ROS release from the IMS to the cytosol (**Figure [6](#F6){ref-type="fig"}**). Several pieces of evidence support the involvement of VDAC1 in ROS release from the IMS to the cytosol, including:

\(i\) HK-I and HK-II bound to VDAC1 decrease ROS release from mitochondria when over-expressed in HEK cells ([@B370]), thereby reducing intracellular levels of ROS ([@B9]; [@B100]). Also, expression of HK-I or HK-II was found to protect against oxidant-induced cell death ([@B9]; [@B62]). Thus, detachment of HK from VDAC1 could lead to increased ROS generation and release to the cytoplasm, thereby activating cell death.

\(ii\) Closure of VDAC appears to impede the efflux of superoxide anions from the IMS, resulting in an increased steady-state level of $\text{O}_{2}^{- \cdot}$, causing internal oxidative stress and sensitizing mitochondria toward the Ca^2+^-induced MPT ([@B382]).

\(iii\) The VDAC inhibitors, DIDS and dextran sulfate, inhibited $\text{O}_{2}^{\cdot}$ release from the mitochondria to the cytosol ([@B170]).

ROS-INDUCED APOPTOSIS IS MEDIATED VIA VDAC1
-------------------------------------------

Mitochondria are the major source of ROS that, when released to the cytosol, can damage proteins, lipids and DNA. ROS release is mediated via VDAC1, with its interactors (e.g., HK, DIDS, RuR, AzRu) inhibiting release (**Figure [7](#F7){ref-type="fig"}**). Mitochondria also contain several enzymes that can decompose ROS. ROS can promote Cyto *c* release from mitochondria ([@B295], [@B294]). In fact, it has been shown that apoptosis-inducing agents, such as inorganic arsenic compounds ([@B333]; [@B119]) and doxorubicin ([@B276]; [@B360]), cause oxidative damage to DNA and protein by inducing ROS generation.

![**Reactive oxygen species occlusion and degradation in mitochondria can prevent cell damage.** A schematic presentation summarizing current knowledge and proposed control mechanisms for ROS production, neutralization, and cellular effects (see VDAC1 Function in ROS Release, ROS-mediated Apoptosis and Interaction with NO). Free radicals generated by the electron transport chain are generally regarded as toxic metabolites and, as such, are degraded by specialized enzymes, namely catalases, peroxidases, superoxide dismutases, and glutathione peroxidase. Mitochondrial ROS cross the OMM via VDAC. The ROS that escapes catalytic removal can cause oxidative damage () to mitochondria, and when released from the mitochondria, can damage cellular proteins, lipids, and DNA. In addition, ROS can induce apoptosis. ROS is proposed to induce Cyto *c* release by oxidizing the mitochondria-specific phospholipid, cardiolipin (CL). ROS-oxidized CL has a markedly lower affinity for Cyto *c*, thus rendering Cyto *c* free in the inter-membrane space. ROS can also induce VDAC oligomerization to yield a mega-channel mediating Cyto *c* release. VDAC inhibitors (e.g., RuR, AzRu, DIDS) and hexokinase (HK) can prevent ROS release to the cytosol. CuZnSOD, cytosolic (copper--zinc-containing) superoxide dismutases; MnSOD, mitochondrial (manganese-containing) superoxide dismutases; GPx, glutathione peroxidase.](fonc-02-00164-g007){#F7}

Inhibition of $\text{O}_{2}^{- \cdot}$-induced apoptosis by DIDS, an inhibitor of VDAC channel activity, or anti-VDAC1 antibodies ([@B349]; [@B241]; [@B339]; [@B356]), suggests that $\text{O}_{2}^{- \cdot}$-induces Cyto *c* release via VDAC-dependent permeabilization of the OMM ([@B241]). Moreover, $\text{O}_{2}^{- \cdot}$ was found to evoke Cyto *c* release in VDAC-reconstituted liposomes ([@B241]). In other studies, it was found that ROS-induced alterations of VDAC1 and/or ANT can induce MMP selective for Cyto *c* release, without causing further mitochondrial damage ([@B241]; [@B219]). In addition, ROS-induced up-regulation of VDAC1 can be prevented by the ROS chelator, epigallocatechin ([@B192]). It has been suggested that ROS-mediated Cyto *c* and SOD1 release from mitochondria involves VDAC, leading to increased susceptibility of mitochondria to oxidative stress and apoptosis ([@B230]).

Interactions between TSPO and VDAC1 are proposed to play a role in apoptosis ([@B139]; [@B396]; [@B228]; see VDAC and the Translocator Protein). TSPO appears to be involved in the generation of ROS, leading to apoptosis induction ([@B398]). It was hypothesized that the close association of TSPO with VDAC may enhance the concentration of ROS generated by TSPO, leading to apoptosis induction ([@B153]; [@B395], [@B397]).

NITRIC OXIDE, MITOCHONDRIA, VDAC AND CELL DEATH
-----------------------------------------------

Nitric oxide (NO) possesses both pro- and anti-apoptotic effects, depending on both cell type and NO concentration ([@B60]; [@B199]). Specific NO molecular targets include inhibition of Bcl-2 cleavage ([@B200]) and inactivation of caspases by *S*-nitrosylation ([@B229]). At low physiological release rates, NO was found to inhibit PTP opening in a reversible manner*,*while at high physiological release rates, NO accelerated PTP opening ([@B58]). VDAC1 was found to bind the endothelial NO synthase (eNOS; [@B369]). *In vitro* binding studies using glutathione *S*-transferase (GST)-tagged VDAC1 indicated that VDAC1 binds directly to eNOS and that this interaction amplified eNOS activity. Furthermore, the calcium ionophores, A23187 and bradykinin, both known to activate eNOS, increased VDAC1--eNOS complex formation, suggesting a potential role for intracellular Ca^2+^ in mediating this interaction ([@B369]). The above results indicate that the interaction between VDAC and eNOS may be important for regulating eNOS activity and modulation of VDAC by NO ([@B369]). Recently, it has been reported that exogenous NO directly interacts with purified VDAC from rat heart and inhibited its channel activity in a biphasic manner. This inhibition was prevented by a NO scavenger. Channel activity inhibition paralleled the delay in opening of the cardiac PTP by NO ([@B79]).

VDAC1 TRANSPORT OF Ca^2+^ AND FUNCTION IN ER--MITOCHONDRIA CROSS-TALK
=====================================================================

MITOCHONDRIAL Ca^2+^ TRANSPORT AND VDAC1
----------------------------------------

Ca^2+^ is a ubiquitous cellular signal, with changes in intracellular Ca^2+^ concentration not only stimulating a number of intercellular events but also triggering cell death pathways, including apoptosis. Ca^2+^ signals result in the regulation of Ca^2+^-dependent enzymes, such as phospholipases, proteases, and nucleases, important during injury or cell death ([@B40]). Apart from their metabolic and apoptotic roles, mitochondria are also a major hub of cellular Ca^2+^ homeostasis. Indeed, mitochondrial Ca^2+^ homeostasis is fundamental for a wide range of cellular activities, such as control of oxidative phosphorylation ([@B94]; [@B239]), modulation of cytosolic calcium signals ([@B161]), cell death ([@B146]), and secretion ([@B242]; [@B221]). Intra-mitochondrial Ca^2+^ controls energy metabolism by enhancing the rate of NADH production by modulating critical enzymes, such as those of the TCA cycle and fatty acid oxidation ([@B271]; [@B108]), linking glycolysis to the TCA cycle ([@B69]).

Ca^2+^ transport across the IMM is mediated by several recently identified proteins. The mitochondrial Ca^2+^ uniporter (MCU; [@B33]; [@B118]), as well as its regulatory protein, the EF hand-containing protein termed MICU1 (for mitochondrial calcium uptake 1), acting as a Ca^2+^ sensor that controls mitochondrial Ca^2+^ entry mediated by the MCU, were identified ([@B326]). The high-affinity mitochondrial Ca^2+^/H^+^ exchanger, Letm1, is able to import Ca^2+^ at low (i.e., sub-micromolar) cytosolic concentrations into energized mitochondria ([@B189]), while the Na^+^/Ca^2+^ exchanger superfamily, NCLX, is the major Ca^2+^ efflux mechanism ([@B281]). All the Ca^2+^ transport systems described above mediate the transport of Ca^2+^ across the IMM (**Figure [1](#F1){ref-type="fig"}**). However, incoming Ca^2+^ must first traverse the OMM. The only identified protein mediating Ca^2+^ transport in the OMM is VDAC1. Indeed, VDAC1 is permeable to Ca^2+^ and possesses Ca^2+^-binding sites ([@B149]; [@B302]; [@B374]) and it has been shown that control of OMM Ca^2+^ permeability is mediated by VDAC ([@B30]; [@B374]).

Ca^2+^, MITOCHONDRIA, APOPTOSIS, AND VDAC
-----------------------------------------

Although changes in mitochondrial Ca^2+^ concentration are known to trigger apoptosis, the precise mechanism is not known.

VDAC1 is highly Ca^2+^-permeable and modulates Ca^2+^ access to the mitochondrial inter-membrane space ([@B149]; [@B374]). Non-physiological Ca^2+^ overload depolarizes mitochondria by opening the PTP, with concomitant release of Cyto *c* and other IMS proteins ([@B95]; [@B34]) that can lead to both apoptotic and necrotic cell death, associated with disease pathogenesis ([@B303]). Thus, Ca^2+^ overload disrupts energy production by mitochondria and enables apoptosis and/or necrosis ([@B347]; [@B201]; [@B303]). Ca^2+^ overload also results in production of ROS. To date, the mitochondrial target for Ca^2+^ activation of Cyto *c* release has not been identified. The inhibition of PTP opening by RuR ([@B149]), while protection against cell death induced by several apoptotic stimuli ([@B24]; [@B120]; [@B23]) may arise from RuR interaction with VDAC1, inducing channel closure ([@B149]). This is supported by the findings that E72Q-VDAC1 did not interact with RuR and cells expressing this mutant were not protected against apoptosis by RuR ([@B435]). These observations suggest that Ca^2+^-binding sites in VDAC1 ([@B186]) serve regulatory functions, including those involved in apoptosis induction.

ER--MITOCHONDRIA Ca^2+^ TRANSPORT, VDAC, AND APOPTOSIS
------------------------------------------------------

The ER is a dynamic reservoir of Ca^2+^ ions with electrical or chemical cell stimulation resulting in its activation ([@B50]; [@B399]), highlighting the role of this organelle as an indispensable component of Ca^2+^ signaling processes. Ca^2+^ originating from the ER has been shown to be a potent death-inducing signal ([@B296]).

The interplay between ER- and mitochondria-mediated Ca^2+^ signaling is a determinant of cellular fate through the control of apoptosis and autophagy ([@B102]). Release of Ca^2+^ from the ER via inositol-1,4,5-trisphosphate receptors (IP~3~Rs) has been observed in models of apoptosis and has been implicated directly in mitochondrial Ca^2+^ overload ([@B165]). The specific sites of physical association between the ER and mitochondria, known as mitochondria-associated membranes (MAMs), include VDAC among the proteins present at these junctions ([@B49]). The mitochondrial chaperone, grp75 (glucose-regulated protein 75), has been proposed to mediate the molecular interaction of VDAC1 with the ER Ca^2+^-release channel, IP~3~R, and that chaperone-mediated conformational coupling of these proteins enables better transfer of the Ca^2+^ ions from the ER to the mitochondria ([@B372]). In a cell-free system containing purified mitochondria, ER vesicles, IP~3~R, and VDAC1, PTP activity was identified as being involved in the ER-triggered pro-apoptotic mitochondrial membrane permeabilization process ([@B106]). It has been recently established that VDAC1 (but not isoforms 2 or 3) selectively interacts with IP~3~Rs and is preferentially involved in the transmission of low-amplitude apoptotic Ca^2+^ signals to mitochondria ([@B117]). The involvement of VDAC1 in ER--mitochondria Ca^2+^ cross-talk places VDAC1 at a crucial position on the route transferring Ca^2+^ signals from the ER to mitochondria, and thus couples ER and mitochondrial functions ([@B117]).

VDAC AS A PHARMACOLOGICAL TARGET FOR COMPOUNDS AFFECTING CELL PROLIFERATION OR APOPTOSIS
========================================================================================

VDAC1, as a multi-functional channel involved both in metabolic homeostasis and apoptosis, can be considered as a prime target for therapeutic agents designed to act via metabolic interference or modulating apoptosis ([@B345]; [@B348]). Indeed, several studies identified pharmacological agents that target VDAC as inducing cancer cell death. These agents can be categorized into the following groups:

ROS-PRODUCING VDAC-DEPENDENT AGENTS
-----------------------------------

Reactive oxygen species has been shown to promote Cyto *c* release from mitochondria, thereby inducing apoptotic cell death ([@B295]; [@B294]) (see VDAC1 Function in ROS Release, ROS-mediated Apoptosis and Interaction with NO). Currently known drugs acting via enhancing ROS production include FNQs, erastin, and As~2~O~3~.

Furanonaphthoquinones were proposed to induce caspase-dependent apoptosis via the production of NADH-dependent ROS. In HeLa cells, FNQs induce mitochondrial swelling, with subsequent apoptosis, while radical scavengers and anti-VDAC1 antibodies reduced this effect ([@B357]), suggesting that FNQ-mediated apoptosis is VDAC-dependent. This claim is further supported by the findings that the ROS production and the anti-cancer activity of FNQs were increased upon VDAC1 over-expression and decreased upon silencing of VDAC1 expression by siRNA ([@B357]). FQNs were found to also up-regulate the pro-apoptotic proteins, Bad, Bax, and Cyto *c*, while down-regulating the anti-apoptotic proteins, Bcl-2, survivin, and XIAP in A549 cells ([@B365]).

Erastin is a cell-permeable piperazinyl--quinazolinone compound that exhibits oncogene-selective lethality toward cells harboring activating mutations in the RAS--RAF--MEK signaling pathway. Erastin treatment in these cells rapidly induces ROS production and a non-apoptotic form of cell death ([@B421]). Knockdown of *vdac2*or *vdac3* caused resistance to erastin, suggesting their involvement in the mechanism of action of erastin ([@B421]). It was also reported that RSL5, a compound that has increased lethality in the presence of oncogenic RAS, and erastin induced VDAC3-dependent cell death ([@B424]). Finally, the erastin analog, PRLX 93936, was found to bind VDAC2 and VDAC3 using a proteomics approach ([@B321]). PRLX 93936 is currently in clinical Phase I for treatment of solid tumors.

As~2~O~3~, a clinically active anti-leukemia agent reported to inhibit mitochondrial respiratory function, increases ROS generation, and enhances the activity of other O~2~^.-^ producing agents against cultured leukemia cells and primary leukemia cells isolated from patients ([@B290]).

CHEMICALS THAT DIRECTLY INTERACT WITH AND MODIFY VDAC ACTIVITY
--------------------------------------------------------------

Various compounds interact with VDAC to modify its activity (**Table [2](#T2){ref-type="table"}**). *Acrolein* (2-propen-1-al), the most reactive of the α,β-unsaturated aldehydes and a toxic compound ([@B5]) that was proposed to react with DNA and proteins, preferential binds at p53 mutational hotspots to inhibit DNA repair ([@B129]). Acrolein is a respiratory irritant that is generated during cooking and is abundant in the environment ([@B187]). The compound is also endogenously generated by lipid peroxidation at sites of injury ([@B5]). In pathological conditions associated with oxidative stress ([@B403]), like spinal cord injury ([@B238]) and Alzheimer's disease ([@B98]), levels of acrolein were found to be elevated. Acrolein is reported to enhance carbonylation of VDAC, an event that was found to be significantly increased in the brains of Alzheimer's disease patients ([@B257]).

###### 

Reagents proposed to act via VDAC (for details, see VDAC as a Pharmacological Target for Compounds Affecting Cell Proliferation or Apoptosis).

  --------------------------------------------------------------------------------------------------------------------------------------------------------------
  Agents                  VDAC-mediated cytotoxic                                                                                              Reference
  ----------------------- -------------------------------------------------------------------------------------------------------------------- -----------------
  Avicins                 Pro-apoptotic plant stress metabolites, target and close VDAC                                                        [@B173]

  Fluoxetine (Prozac)     Anti-depressant induces cell proliferation and cell-line dependent apoptotic modulator.\                             [@B268]
                          Interacts directly with VDAC, inhibits PTP opening and apoptosis                                                     

  Cisplatin               Interacts directly with VDAC1 and inhibits PTP opening                                                               [@B73], [@B425]

  Acrolein                α,β-Unsaturated aldehydes, carbonylates VDAC in Alzheimer's disease                                                  [@B257]

  Erastin                 Anti-cancer agent that binds directly to VDAC2 to induce cell death                                                  [@B421]

  Endostatin              Small collagen type XVIII fragment, angiogenesis inhibitor. Interacts with VDAC1, inducing PTP opening               [@B433]

  Oblimersen              18-mer phosphorothioate anti-sense oligonucleotide. Binds directly to VDAC, blocks channel activity, pro-apoptotic   [@B375]

  Furanonaphthoquinones   Induce caspase-dependent apoptosis. FNQ-mediated apoptosis is VDAC-dependent                                         [@B357]

  Geldanamycin 17AAG      Binds to VDAC and inhibits cell invasion                                                                             [@B418]
  --------------------------------------------------------------------------------------------------------------------------------------------------------------

*Avicins* represents a family of triterpenoid saponins, plant stress metabolites that exhibit cytotoxic activity in tumor cells. These compounds possess anti-inflammatory and anti-oxidant properties capable of perturbing mitochondrial function and initiating apoptosis in tumor cells ([@B135]; [@B174]). Avicin G reduces VDAC1 channel conductance, ATP levels, and respiration rates in Jurkat cells ([@B227]; [@B173]).

*Cisplatin* (*cis*-diamminedichloro platinum(II)) is a widely used anti-cancer drug that trigger apoptosis ([@B325]). Cisplatin acts by forming inter- and intra-strand nuclear DNA cross-links upon binding ([@B437]). Mitochondria, however, have been implicated as a cisplatin target, leading to apoptosis induction ([@B425]; [@B97]). Cisplatin binds to mitochondrial DNA and VDAC ([@B425]) to regulate VDAC activity ([@B73]). Thus, it was proposed that VDAC acts as a cisplatin receptor during apoptosis ([@B380]). Recently it was suggested that over-expression of SCIN, a calcium-dependent actin-binding protein, is a novel cisplatin-resistant marker in the human bladder cancer cell line, HT1376 ([@B262]). It was proposed that the high expression of SCIN and its interaction with VDAC mediates resistance to cisplatin ([@B262]).

*Endostatin* is a naturally occurring 20 kDa C-terminal fragment derived from type XVIII collagen that may interfere with the pro-angiogenic action of growth factors ([@B130]). Endostatin has a wide range of anti-cancer spectrum targets ([@B193]). Decreasing VDAC1 levels by siRNA attenuates endostatin-induced apoptosis, while over-expression of VDAC1 enhances the sensitivity of endothelial cells to endostatin ([@B433]). Endostatin was found to induce PTP opening through VDAC1 ([@B433]). These findings point to VDAC1 as endostatin target.

*Fluoxetine* (also known as Prozac, Sarafem, Fontex) is an anti-depressant, acting as a selective serotonin re-uptake inhibitor and is clinically used to treat different major depressions, obsessive-compulsive disorder, bulimia nervosa, and panic disorders, among other psychiatric conditions ([@B414]). The connection between fluoxetine and apoptosis is clouded by a series of contradictory findings. Fluoxetine was reported to enhance apoptosis in different cancer cells and tumors ([@B86]; [@B222]; [@B132]), yet was suggested to prevent apoptosis in both cancerous and neuronal cells ([@B415]; [@B223]; [@B81]; [@B407]). Fluoxetine was shown to interact with VDAC1 and to increase the voltage-dependence of bilayer-reconstituted VDAC1 ([@B268]; [@B379]). Additionally, fluoxetine was shown to prevent PTP opening and inhibited the release of Cyto *c* and apoptosis ([@B268]). Although its remains unclear as to whether fluoxetine has an anti- or pro-apoptotic effect, it does seem that the compound mediates its effect on apoptosis via interactions with VDAC1.

*Oblimersen* (G3139) is an 18-mer phosphorothioate anti-sense oligonucleotide being studied as a possible treatment for several types of cancer, including CLL ([@B8]), B cell lymphoma ([@B298]), breast cancer ([@B308]), and melanoma ([@B217]). Although oblimersen is designed to target the initiation codon region of Bcl-2 mRNA, it was found to directly interact with VDAC1 and reduce its channel activity ([@B217]; [@B375]). Oblimersen is reported to induce caspase-dependent apoptosis via the intrinsic mitochondrial pathway in a Bcl-2-independent mechanism ([@B217]).

*Geldanamycin* (17AAG) is a derivative of the antibiotic, ansamycin. Geldanamycin binds to a conserved pocket in the amino-terminal portion of the Hsp90 chaperone protein and inhibits its function ([@B185]). *In vitro*, 17AAG acted as a Ca^2+^ mitochondrial regulator, increasing intracellular Ca^2+^ and diminishing the plasma membrane cationic current ([@B418]). 17AAG was shown to interact with VDAC through a hydrophobic interaction that was independent of Hsp90. This interaction was proposed to mediate inhibition of glioblastoma cell invasion ([@B418]).

FINAL PERSPECTIVE
=================

In recent years, we have witnessed a switch in the focus of VDAC research from channel activity properties and regulation at the level of purified protein in yeast and *Neurospora* to studying its function in mammalian cell cultures and animal models. Indeed, a significant accumulation of knowledge is now available concerning VDAC1 function in cell life and death. Much has been learned about VDAC function in regulating metabolite cross-talk between the mitochondria and rest of the cell, its function in mitochondria--ER Ca^2+^ signaling, its function in apoptosis and its involvement in various maladies from neurodegenerative diseases to cancer. The studies reviewed above have demonstrated the pivotal roles of mitochondria and VDAC1 in cancer. The dual functions of VDAC1 in both metabolism and apoptosis, as mediated by the protein alone and regulated by associated polypeptides, point to VDAC1 as begin a critical target in addressing cancer therapy.

Although a high-resolution structure was determined for recombinant VDAC1, many questions concerning the architecture of the channel pore, the location of modulator-binding sites, the protein regions involved in the control mechanism of VDAC1 oligomerization and how VDAC is regulated to serve its multiple roles remain unanswered. Likewise, additional studies are required to investigate whether the increased dependence of cancer cells on glycolytic metabolism can be exploited therapeutically.

VDAC1 is integral to mitochondrial ATP production as a metabolite transporter, as the docking site for mitochondrial-bound HK, and is highly expressed in cancers. VDAC1 is associated with the mitochondrial pathway of apoptosis, interacting with over-expressed anti-apoptotic proteins present in cancer and mediating the actions of some anti-cancer drugs. In addition, VDAC1 mediates cholesterol transport and distribution in the mitochondrial membrane, with cancer cells exhibiting several fold higher cholesterol levels than do healthy cells. VDAC1 also functions in ROS production and transport to the cytosol, with elevated ROS generation being seen in cancer cells. These functions, together with VDAC1 being over-expressed in some cancer cells, point to VDAC1 as being a rational target for the development of a new generation of therapeutics.

Delineating the molecular mechanisms underlying the re-programmed metabolism seen in cancers and their cell survival strategies, together with increasing understanding of the difficulty in targeting signal transduction in tumors without significant side-effects, encourages prospects for the development of effective cancer therapies. Thus, the emergence of targeted therapies specifically targeting critical molecules important for cancer cells may provide promising means of selectively killing these malignant cells. VDAC1 is one such a target. Indeed, various strategies involving interference RNA to down-regulate VDAC1 expression levels, VDAC1-based peptides and small molecules, such as methyl jasmonate, are being considered in this capacity. Finally, the discovery that VDAC plays a role at critical control points during energy metabolism and in apoptosis points to VDAC as a novel pharmacologic target for anti-cancer drugs.
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AIF

:   apoptosis-inducing factor

ANT

:   adenine nucleotide translocase

APAF-1

:   apoptosis protease-activating factor 1

Bcl-2

:   B cell lymphoma 2

caspase

:   cysteinyl/aspartate-specific protease

CLL

:   chronic lymphocytic leukemia

CyP D

:   cyclophilin D

Cyto *c*

:   cytochrome *c*

DIDS

:   4,4′-diisothiocyanatostilbene-2,2′-disulfonic acid

ER

:   endoplasmic reticulum

FNQs

:   furanonaphthoquinones

G-6-P

:   glucose-6-phosphate

HK

:   hexokinase

IMM

:   inner mitochondrial membrane

IP~3~Rs

:   inositol-1,4,5-trisphosphate receptors

LDH

:   lactate dehydrogenase

MAC

:   mitochondrial apoptosis-inducing channel

NSCLC

:   non-small cell lung cancer

OMM

:   outer mitochondrial membrane

PDH

:   pyruvate dehydrogenase

PLB

:   planar lipid bilayer

PT

:   permeability transition

PTP

:   permeability transition pore

ROS

:   reactive oxygen species

RuR

:   ruthenium red

SR

:   sarcoplasmic reticulum

STS

:   staurosporine

TNF-α

:   tumor necrosis factor alpha

TSPO

:   translocator protein

UCP

:   uncoupling protein

VDAC

:   voltage-dependent anion channel.
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